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ABSTRACT OF DISSERTATION 
 
 
 
 
 
NONCONTACT DIFFUSE CORRELATION TOMOGRAPHY  
OF BREAST TUMOR 
 
 
 
Since aggressive cancers are frequently hypermetabolic with angiogenic vessels, 
quantification of blood flow (BF) can be vital for cancer diagnosis. Our laboratory has 
developed a noncontact diffuse correlation tomography (ncDCT) system for 3-D imaging 
of BF distribution in deep tissues (up to centimeters). The ncDCT system employs two 
sets of optical lenses to project source and detector fibers respectively onto the tissue 
surface, and applies finite element framework to model light transportation in complex 
tissue geometries. This thesis reports our first step to adapt the ncDCT system for 3-D 
imaging of BF contrasts in human breast tumors. A commercial 3-D camera was used to 
obtain breast surface geometry which was then converted to a solid volume mesh. An 
ncDCT probe scanned over a region of interest on the breast mesh surface and the 
measured boundary data were used for 3-D image reconstruction of BF distribution. This 
technique was tested with computer simulations and in 28 patients with breast tumors. 
Results from computer simulations suggest that relatively high accuracy can be achieved 
when the entire tumor was within the sensitive region of diffuse light. Image 
reconstruction with a priori knowledge of the tumor volume and location can 
significantly improve the accuracy in recovery of tumor BF contrasts. In vivo ncDCT 
imaging results from the majority of breast tumors showed higher BF contrasts in the 
tumor regions compared to the surrounding tissues. Reconstructed tumor depths and 
dimensions matched ultrasound imaging results when the tumors were within the 
sensitive region of light propagation. The results demonstrate that ncDCT system has the 
potential to image BF distributions in soft and vulnerable tissues without distorting tissue 
hemodynamics. In addition to this primary study, detector fibers with different modes 
(i.e., single-mode, few-mode, multimode) for photon collection were experimentally 
explored to improve the signal-to-noise ratio of diffuse correlation spectroscopy flow-
oximeter measurements. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Classification of Breast Disease 
The main function of the breasts is to make milk for breastfeeding. Glandular tissues 
and supporting (stromal) tissues are two main types of tissues in breasts (1). The 
glandular part of the breast includes the lobules and ducts (Figure 1.1). In women who 
are breastfeeding, the cells of the lobules make milk. The milk then moves through the 
ducts, which are tiny tubes that carry milk, to the nipple. Each breast has several ducts 
that lead out to the nipple. The support tissue of the breast includes fatty tissue and 
fibrous connective tissue that give the breast its size and shape. 
 
Figure 1 
Figure 1.1: A schematic representation of the breast (1). 
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Changes in the breasts may be caused either by benign conditions or cancer. Most 
breast lesions detected are benign, which don’t grow uncontrollably or spread, but they 
may be linked to breast cancer risk (2, 3). Benign breast diseases constitute 
heterogeneous groups of lesions including developmental abnormalities, inflammatory 
lesions, fibrocystic changes, proliferative stromal lesions, and neoplasms (3). Ectopic 
breast, which has been described as both supernumerary and aberrant breast tissue, is the 
most common congenital abnormality of the breast. Supernumerary breast tissue is seen 
mostly along the milk line; the most frequent sites are the chest wall, vulva, and axilla. 
However, malignancies in ectopic breasts are very rare (4, 5). Inflammatory and related 
lesions include mastitis, mammary duct ectasia and fat necrosis. Among those, mastitis is 
often caused by a breast infection and is most often seen in lactating women. Although 
mastitis does not raise a women’s risk of developing breast cancer, an uncommon type of 
inflammatory breast cancer has symptoms that are a lot like mastitis. Mammary duct 
ectasia also called periductal mastitis. The most important histological feature of this 
disorder is the dilatation of major ducts in the subareolar region. There is no evidence 
indicating it is associated with an increased risk for breast cancer. Fat necrosis of the 
breast is a benign nonsuppurative inflammatory process of adipose tissue. Fibrocystic 
changes constitute the most frequent benign disorder of the breast. They comprise both 
cysts and solid lesions, including adenosis, epithelial hyperplasia with or without atypia, 
apocrine metaplasia, radial scar, and papilloma. In order to determine the risk factors for 
fibrocystic changes, they are subdivided into nonproliferative lesions, proliferative 
lesions without atypia, and proliferative lesions with atypical (atypical hyperplasia) (6-8). 
Proliferative stromal lesions include diabetic fibrous mastopathy and pseudoangiomatous 
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stromal hyperplasia of the breast. Neoplasms include fibroadenoma, lipoma, adenoma, 
hamartoma and granular cell tumor. Specifically, fibroadenoma is the most common 
lesion of the breast and it occurs in 25% of asymptomatic women. The peak incidence of 
fibroadenoma is between the ages of 15 and 35 years. 
Breast cancer begins in the lobules and ducts (Figure 1.1). According to the extent of 
spread, breast cancer can be determined as in situ (noninvasive) or invasive. For in situ 
breast cancers, there are abnormal breast changes in the cells lining the breast ducts or 
lobules. The noninvasive breast tumors include ductal carcinoma in situ (DCIS), lobular 
carcinoma in situ (LCIS), and other in situ breast cancers have characteristics of both 
DCIS and LCIS.  For invasive breast cancers, the abnormal cells have broken through the 
ductal or glandular walls and grown into surrounding breast tissue. Invasive breast 
cancers include ductal carcinoma, which is the most common type, invasive lobular 
carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma and invasive 
papillary carcinoma (9). 
 
1.2 Medical Imaging for Breast Tumor 
About 1 in 8 women in the United States will develop invasive breast cancer over her 
lifetime. Its high incidence and associated mortality makes it an important public health 
problem (2, 10). Finding breast cancers when they remain localized results in 5-year 
relative survival rates of 99% (2). The current clinical standard for breast screening is x-
ray mammography which can often identify cancer several years before physical 
symptoms develop (2). The significant decrease in breast cancer mortality, which 
amounts to nearly 30% since 1990, is due in large part to the earlier detection of breast 
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cancer through mammographic screen (11). However, mammography is hampered by a 
significant false-positive rate, which is especially high for women with dense breast 
tissue. The dense breast population is a particularly important subset of women because 
they experience higher incidence and mortality rates from the disease (12, 13).  
Other imaging modalities used as adjunctive screening tools for breast cancers 
include x-ray computed tomography (CT), magnetic resonance imaging (MRI), positron 
emission tomography (PET) and ultrasonography (14-16). For women with dense breasts, 
ultrasound imaging yields an incremental cancer detection rate. However, there are issues 
related to high false-positive rates, operator dependency of the examination and inability 
to image most DCIS. For women with the highest risk of developing breast cancer, 
screening MRI is adopted to provide higher screen sensitivity. However, considerable 
cost (i.e., larger than $50,000 per cancer) is added. PET scan can provide physiological 
information on the uptake of glucose and its metabolism, both of which are increased in 
malignant tissue (17). Combined PET/CT systems are increasingly available, which fuse 
PET and CT images to provide combined physiologic and anatomic imaging (18). 
However, both PET and CT are not used for primary tumor detection (invasive tumor 
with diameter smaller than 1 cm) and they are recommended for detection of metastases 
and recurrent disease in breast cancer (17, 18).  
 
1.3 Optical Imaging for Breast Tumor 
Optical imaging is currently emerging as a promising new addition to medical 
imaging, which provides biologists and clinicians new ways to detect, diagnose and study 
disease (19). Optical microscopy imaging with high spatial resolution for cancer research 
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has been paid much attention in the past few decades (20-23). Laser scanning confocal 
fluorescence microscopy provides high resolution, depth resolved, 3-D images (24). 
Two-photon fluorescence microscopy has later been invented which reduced photo 
damage compared with fluorescence confocal microscopy and achieves even higher 
spatial resolution and deeper penetration into tissues (20). Optical coherence tomography, 
which is analogous to ultrasound, performs high resolution cross-sectional imaging of 
tissue scattering (21, 22). While these techniques are all extremely useful, they have a 
common limitation. They can only be used to image tissue near the surface. Confocal 
microscopy penetrates up to depths of about 50 µm. Two-photon microscopy allows one 
to look slightly deeper, up to hundreds of micrometers. OCT goes even deeper, but only 
to depths of at most 2-3 mm in highly scattering tissue. The shallow imaging depth 
inhibits the use for non-destructive in vivo imaging of breast tumor.  
On the other hand, macroscopic imaging allows for larger fields of view and deeper 
depths of penetration ranging from millimeters to centimeters. Photoacoustic tomography 
(PAT) combines ultrasonic-scale resolution and penetration depth with high sensitivity to 
tissue light absorption (25-27). For breast tissue imaging, PAT can visualize vasculature 
inside the tissue by virtue of its high hemoglobin content compared to surrounding breast 
parenchyma (19, 28-30). However, most currently available PAT systems require the 
tissue and ultrasonic detectors to be in contact with a coupling fluid, complicating 
experimental procedures. Diffuse correlation spectroscopy (DCS) and near-infrared 
spectroscopy (NIRS) have been developed to probe blood flow ， hemoglobin 
concentration and oxygen saturation in deep tissue vasculature (several centimeters). A 
well-known ‘biological window’ exists in the NIR range (600-900 nm) (Figure 1.2), 
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wherein tissue absorption is relatively low, so that light can penetrate into deep/thick 
volumes of tissue (31). For imaging with NIRS/DCS (i.e., diffuse optical/correlation 
tomography [DOT/DCT]), multiple points on the tissue boundary are usually illuminated 
in a time-sharing fashion and diffuse light patterns are collected around the boundary 
using photodetector sets. NIRS/DOT has been used over decades to detect oxygenation 
alternations in breast tumors (32-36).  
 
 
Figure 2 
Figure 1.2: Absorption Spectra of Hemoglobin and Water. Tissue absorption coefficients 
(µa) shown as a function of wavelength (λ) for oxygenated hemoglobin (HbO2), 
deoxygenated hemoglobin (Hb), and water (H2O).  Within the NIR spectral window 
(~600 – 900 nm), light is able to penetrate deep tissue due to low absorption.  
 
1.4 Diffuse Correlation Spectroscopy (DCS) 
DCS is an emerging new technique which provides direct measurement of blood flow 
index (BFI) in deep tissues (37-43). DCS takes advantage of the same biological window 
Biological Window
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as traditional NIRS techniques, but employs long-coherence (˃ 5 meter) NIR continuous-
wave laser as the light source. DCS blood flow measurement is accomplished by 
monitoring speckle fluctuations of photons resulting from moving scatterers in biological 
tissues. Moving red blood cells (RBCs) inside vessels are primarily responsible for these 
fluctuations. In most dynamic experiments, the temporal statistics of light speckle 
fluctuations are monitored and the electric field temporal autocorrelation function or its 
Fourier transform is quantified. Using a correlation diffusion equation describing the 
propagation of electric field temporal autocorrelation function through tissues, the 
measured signal is then related to the motion of RBCs and, consequently, BFI is 
determined. Relative change in blood flow (rBF) can then be determined by normalizing 
BFI to its baseline value (e.g. before physiological change). DCS provides several 
attractive new features for blood flow measurement in tissue microvasculature, including 
noninvasiveness (i.e., no ionizing radiation, no contrast agents), high temporal resolution 
and relatively high penetration depth (up to several centimeters (44)).  
DCS technology has been extensively validated in various tissues through 
comparisons with laser Doppler flowmetry (45, 46), Doppler ultrasound (47, 48), power 
Doppler ultrasound (49, 50), Xenon-CT (51), fluorescent microsphere flow measurement 
(52), and arterial spin labeled magnetic resonance imaging (39, 44). 
Since measurements of blood flow provide insight about oxygen delivery and the 
clearance of metabolic by-products (53), in vivo diffuse optical measurement of blood 
flow has been explored for tumor characterization and prediction of treatment outcomes 
(54). A few pilot studies of breast tumors using DCS have found increased blood flow 
inside the tumor in contrast to surrounding normal tissues (53, 55). Real-time monitoring 
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of breast tumor blood flow response to neoadjuvant chemotherapy also demonstrated the 
potential of DCS for assessing cancer therapies (56, 57). 
 
1.5 Current Study Limitations and Thesis Outline 
Despite advances in DCS technologies, there have been limited imaging applications 
of DCT for tumor detection. An early probe-tissue contact based DCT approach was 
applied to tissue phantoms (58), but was disadvantaged in vivo due in part to 
compression-induced hemodynamic alterations. A few noncontact-based DCT 
examinations have been conducted using the camera lenses positioned between a sample 
and optical fibers connected to source and detection elements (59, 60). These 
arrangements, however, were only tested on the brain of small animals with limited 
probing depth (< 5 mm). Another limitation of these imaging studies was their reliance 
on analytical solutions that assumed a simple semi-infinite flat tissue geometry. As such, 
there have been no reports of studies using DCT for 3-D imaging of blood flow 
distributions in tumors (54). 
The focus of my graduate work is to develop a novel noncontact DCT (ncDCT) 
system for 3-D imaging of tumor-to-normal blood flow in deep tissues and apply the 
system to clinical diagnosis of breast tumors. I have contributed to the development of 
DCT theory, to the design and validation of the imaging system (computer simulations 
and tissue phantom experiments) and to the clinical applications of diffuse optical 
techniques (patients with breast tumors). In addition, I have also explored the use of 
different mode fibers for photon collection to improve the signal-to-noise ratio (SNR) of 
DCS flow-oximeter measurements. In this thesis, I summarize these technique 
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developments and report our first step to adapt the ncDCT system for 3-D imaging of 
blood flow contrasts in human breast tumors. 
This thesis is organized into the following chapters. Chapter 2 describes the 
theoretical background of NIRS and DCS and the development of DCT for 3-D flow 
contrast imaging. Chapter 3 depicts the ncDCT instrumentation, measurement procedures 
and initial validation work on tissue-like phantoms under semi-infinite geometry. The 
recipes and fabrication procedures for making liquid and solid phantoms are also 
included in the appendix. In Chapter 4, further computer simulations are performed to 
characterize the performance of ncDCT system for imaging an anomaly (tumor) with 
varied flow contrasts and depths inside the tissue volumes with breast-shaped surface 
boundaries. Chapter 5 presents in vivo imaging results of blood flow distribution in 28 
human breast tumors using ncDCT. Chapter 6 demonstrates the possibility of improving 
SNRs of DCS flow-oximeter measurements using single-, few- and multi-mode fibers for 
detection. Finally, chapter 7 summarizes the novelties of the present work, my 
contributions to the field, study limitations as well as directions for future research. 
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CHAPTER 2 DIFFUSE CORRELATION SPECTROSCOPY AND 
TOMOGRAPHY: THEORY  
 
2.1 Introduction 
In this chapter I provide a theoretical background for the traditional diffuse optical 
techniques, including NIRS for tissue optical properties and consequently absolute 
oxygenation measurements (Chapter 2.2) and single-wavelength DCS for flow 
monitoring (Chapter 2.3). Contributions to further development of DCS/DCT 
technologies are then presented including (1) an ncDCT technique for 3-D flow imaging 
of deep tissue based on finite element framework (Chapter 2.4.1) and (2) a noise model 
for ncDCT for evaluating the influence of measurement noises on image reconstruction 
accuracy (Chapter 2.4.2). 
 
2.2 NIRS  
The ‘biological window’ in NIR (600-900 nm, see Figure 1.2) has made possible the 
application of diffuse optical imaging and spectroscopy in biological tissues. In this 
window, the absorption coefficients (𝜇𝑎) of water and hemoglobin are low, allowing 
photons to travel deeply into tissues (millimeters to centimeters depending on the 
wavelength used and tissue optical properties) (61). However, due to the factor that 
reduced scattering length (1 𝜇𝑠′⁄ ≈ 1 𝑚𝑚) is much shorter than the absorption length 
(1 𝜇𝑎⁄ ≈ 100 𝑚𝑚), scattering events dominate the propagation of photons inside the 
tissue. Beyond a few millimeters deep inside tissue, the photons may have been scattered 
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multiple times and their directions become random. Thus, the photon propagation in 
tissue over a long distance can be treated as a diffusive process (62, 63). 
The propagation of photons in highly scattering media such as biological tissues can 
be modeled by the diffusion approximation to the radiative transport equation (63, 64). 
This diffusion equation, which governs the photon fluence rate, Φ (𝒓, 𝑡) [𝑊𝑎𝑡𝑡 ∙  𝑐𝑚−2] 
inside the medium, is written in the frequency domain (FD: using modulated light as the 
source) as follows (63, 65): 
∇ ∙ (𝐷(𝒓)∇Φ(𝒓, 𝑡)) − 𝜐𝜇𝑎(𝒓)Φ(𝒓, 𝑡) + 𝜐𝑆(𝒓, 𝑡) =
𝜕Φ(𝒓,𝑡)
𝜕𝑡
               (2.1) 
Here, 𝒓 is the position vector, t [s] is time and υ [cm ∙ 𝑠−1] is the speed of light in the 
medium. 𝜇𝑎(𝒓) [𝑐𝑚
−1] is the absorption coefficient, and 𝐷(𝒓) ≡ 𝑣 3(𝜇𝑎(𝒓) + 𝜇𝑠
′(𝒓))⁄ ≈
𝑣/3µ𝑠
′ (𝒓) [𝑐𝑚2 ∙ 𝑠−1 ] is the photon diffusion coefficient, where 𝜇𝑠
′(𝒓) [𝑐𝑚−1 ] is the 
reduced scattering coefficient of the tissue. S(𝒓, 𝑡)[𝑊𝑎𝑡𝑡 ∙  𝑐𝑚−2] is the isotropic source 
term which gives the number of photons emitted at position r and time t per unit volume 
per unit time. The right hand side of Equation 2.1 shows the change rate of photons 
within a sample volume. This rate equals the number of photons scattered into the 
volume per unit time from its surroundings, minus the number of photons absorbed per 
unit time within the volume, plus the number of photons emitted per unit time from any 
sources in the volume (65). This diffusion approximation is valid when 𝜇𝑎 ≪ 𝜇𝑠
′  and the 
distance between sources and detectors is much greater than the random walk step length 
(~ 1 mm in breast tissue). 
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For point sources of the form 𝑆(𝒓, 𝑡) = 𝑆0𝛿(𝒓 − 𝒓𝑠)exp(−i𝜔t) , where 𝑆0  is a 
constant, 𝜔  is the modulation frequency and 𝑟𝑠  is the source location,  Equation 2.1 
simplifies to (66): 
∇ ∙ ((
𝐷(𝒓)
𝜐
) ∇Φ(𝒓)) − (𝜇𝑎(𝒓) +
𝑖𝜔
𝜐
)Φ(𝒓) = 𝑆0𝛿(𝒓 − 𝒓𝑠)                (2.2) 
where Φ(𝒓, 𝑡) = Φ(𝒓)exp(−i𝜔t).  
To apply the NIR technique for measuring tissue absorption and scattering, 
photodetectors were typically used to detect the diffused light at known distances of a 
few millimeters to centimeters from point sources. Figure 2.1a shows a simple 
measurement setup with one pair of source and detector in reflection geometry. Light 
injected into the tissue through a source fiber can be detected by the detector fiber placed 
at a distance ρ from another fiber. The sensitive region of diffuse light is usually 
described as a “banana pattern” with the penetration depth of ~ρ/2 (65, 67, 68) (see 
Figure 2.1a). The analytical solution for Equation 2.2 in this semi-infinite geometry can 
be obtained (69): 
Φ(𝜌) =
𝑣𝑆0
4𝜋𝐷
(
exp (−𝐾𝑟1)
𝑟1
−
exp (−𝐾𝑟2)
𝑟2
)                                 (2.3) 
where 𝐾2 = 3𝜇𝑠
′(−
𝑖𝜔
𝑣
+ 𝜇𝑎) , 𝑟1 = √𝜌2 + 𝑧0
2  and 𝑟2 = √𝜌2 + (𝑧0 + 2𝑧𝑏)2 , 𝜌  is the 
distance from the source to detector measured along the sample surface,  𝑧𝑏  is the 
distance above the tissue surface at which the fluence rate extrapolates to zero and 𝑧0 is 
the effective depth of the source. We use 𝑧0 = 1 𝜇𝑠
′⁄  and 𝑧𝑏 =
2
3𝜇𝑠
′
1+𝑅𝑒𝑓𝑓
1−𝑅𝑒𝑓𝑓
, 𝑅𝑒𝑓𝑓 =
−1.44𝑛−2 + 0.71𝑛−1 + 0.668 + 0.064𝑛 , 𝑛 ≈ 1.33(for both tissue and phantom). The 
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𝑅𝑒𝑓𝑓  term accounts for the mismatch between the medium and the air indices of 
refraction with 𝑛 being the ratio between them. 
Multidistance measurements of the phase and the amplitude of the photon fluence rate 
 Φ(𝒓, 𝑡) with FD system enable to extract optical properties (𝜇𝑠
′  and 𝜇𝑎) of the measured 
medium by fitting the known analytical solution (Equation 2.3) to the measured 
boundary data (70-72). In the NIR region, the dominant chromophore in tissue is 
hemoglobin (deoxyhemoglobin Hb and oxyhemoglobin HbO2). Since the absorption 
spectra of Hb and HbO2 are different (see Figure 1.2) (62), the concentrations of [Hb] 
and [HbO2] in biological tissue can be calculated by knowing 𝜇𝑎 at two wavelengths (46, 
73). Total hemoglobin concentration (THC) and blood oxygen saturation (StO2) can be 
derived based on [Hb] and [HbO2] consequently. 
Besides the modulated light used in the FD system, there are other two types of light 
sources commonly used in diffuse optics: continuous-wave (CW) and time-resolved (TR) 
(see Figures 2.1b-2.1d) (19, 74). The simplest type is CW light where the light intensity 
remains constant over time. CW systems enable fast data acquisition and the use of 
simple detectors and detection electronics, but cannot determine 𝜇𝑎and 𝜇𝑠
′  simultaneously. 
The FD paradigm uses intensity modulated light to illuminate the tissue, and measures 
both light intensity attenuation and phase shift at the detector, allowing simultaneously 
determination of 𝜇𝑎and 𝜇𝑠
′ . The TR light source delivers short light pulses to the medium, 
which are temporally broaden as they propagate through the medium. At the detector, the 
detected temporal pulse shape contains the information to determine 𝜇𝑎 and 𝜇𝑠
′ . TR 
system yields more output than other two modalities but require more complicated 
equipment and data analysis. 
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Figure 3 
Figure 2.1: Sample input and output intensity signals representing the three types of 
NIRS techniques. Panel (a) is computer simulated “banana pattern” showing the sampled 
volumes in the reflection geometries. Panel (b) shows a CW NIRS, in which attenuated 
intensity of continuous illumination is monitored.  Panel (c) shows FD NIRS, in which 
input light is modulated and the amplitude attenuation and phase shifts are detected.  
Panel (d) shows TR NIRS, in which an impulse of light is emitted into the tissue, and the 
intensity change with respect to time is detected. Here, I0 and I represent input and 
detected intensities, Φ0 represents phase, and M0 represents the frequency of modulation. 
 
2.3 DCS 
Similar to CW NIRS, DCS also utilizes NIR light and the same measurement 
geometry to probe deep tissue properties. While NIRS employs the static method of 
diffuse optical technique to detect slow intensity variations induced by tissue absorption 
and scattering, DCS uses the dynamic method to monitor the fast motion of red blood 
cells.  
When using DCS to detect tissue blood flow, a pair of source and detector fibers is 
usually placed along the tissue surface with separation distance of a few millimeters to 
centimeters. NIR light generated by a CW long coherent laser (coherence length > 5 m) 
emits into tissues through the source fiber. The diffused light transported throughout the 
tissue is detected by a single or few-mode fiber connected to a single-photon-counting 
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detector. Photons travel inside tissue in a diffusive manner (45, 65), and experience 
absorption by tissue absorbers (e.g., hemoglobin and water) and, more often, scattering 
by static or dynamic scatterers (e.g., organelles, mitochondria, moving red blood cells) 
(see Figure 2.2a). The motions of moving scatterers cause temporal fluctuations in light 
intensity, leading to changes in the speckle pattern of interference (38, 41, 54, 58, 65, 67, 
75-78). In most dynamic experiments the temporal statistics of light speckle fluctuations 
are monitored and the electric field temporal autocorrelation function or its Fourier 
transform is quantified. Using a correlation diffusion equation describing the propagation 
of electric field temporal autocorrelation function through tissues, the measured signal is 
then related to the motion of RBCs and, consequently, blood flow is determined. 
The normalized light intensity temporal autocorrelation function is calculated to 
characterize these speckle intensity fluctuations at multiple delay time τ:  
𝑔2(𝒓, 𝜏) = 〈𝐼(𝒓, 𝑡) ∙ 𝐼(𝒓, 𝑡 + 𝜏)〉/〈𝐼(𝒓, 𝑡)〉
2                              (2.4) 
Here 𝐼(𝒓, 𝑡) is the detected light intensity at position 𝒓 and time t, and   denotes a 
time average (38). Faster intensity fluctuations, which are associated with higher blood 
flow, correspond to steeper decay in 𝑔2(𝒓, 𝜏) curve (Figures 2.2b and 2.2c). 
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Figure 4 
Figure 2.2: (a) Schematic for multiple scattering along a single photon path in a turbid 
media with semi-infinite reflection geometry. Solid green line indicates the photon path 
at time t, while the dashed green line represents the photon path at time t+τ. The red and 
grey disks indicate blood cell at time t and t+τ, the blood cell is scattered certain distance 
during the delay time τ (indicated by blue arrows). (b) Example of detected light intensity 
fluctuations from measurements with higher (blue curve) and lower (red curve) blood 
flow. (c) Normalized intensity autocorrelation functions 𝑔2(𝒓, 𝜏) calculated from detected 
light intensities in (b). The decay of the intensity autocorrelation function curves is 
related to the tissue blood flow.  
 
 
In order to extract blood flow information from measured 𝑔2(𝒓, 𝜏)  curve, the 
normalized electric field temporal autocorrelation function 𝑔1(𝒓, 𝜏) = 𝐺1(𝒓, 𝜏) 𝐺1(𝒓, 0)⁄ , 
which contains the information of red blood cell motion, is derived with a correlation 
diffusion approach (65). The blood flow index (BFI) is ascertained by fitting the 
analytical expression of 𝑔1(𝒓, 𝜏)  to the experimentally measured 𝑔2(𝒓, 𝜏)  using the 
Siegert relation (79):  
𝑔2(𝒓, 𝜏) = 1 + 𝛽|𝑔1(𝒓, 𝜏)|
2                                           (2.5) 
Here, 𝛽 = 1 𝑁⁄  is a coherence factor depending mainly on the laser coherence and 
detection optics, and is inversely proportional to the number of guided modes/speckles (N) 
(80). It can be determined experimentally from measured 𝑔2(𝒓, 𝜏) via 𝛽 = 𝑔2(𝒓, 𝜏) − 1.  
The analytical expression of 𝑔1(𝒓, 𝜏) is converted from the electric field temporal 
autocorrelation function 𝐺1(𝒓, 𝜏)= 〈𝐸(𝒓, 𝑡) ∙ 𝐸
∗(𝒓, 𝑡 + 𝜏)〉.  In order to model the 
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propagation of 𝐺1(𝒓, 𝜏)  in biological tissues, the correlation diffusion equation in 
homogeneous medium for CW light source is developed (38, 58, 81):  
𝛻 ((
𝐷(𝒓)
𝑣
)𝛻𝐺1(𝒓, 𝜏)) − (𝜇𝑎(𝒓) +
1
3
𝜇𝑠
′(𝒓)𝑘0
2𝛼〈∆𝑟2(𝜏)〉)𝐺1(𝒓, 𝜏) =  −𝑆0𝛿(𝒓)          (2.6) 
where 𝑣 is the light speed in the medium, 𝑆0𝛿(𝒓) is the CW source term and 𝑆0  is a 
constant, 𝑘0 = 2𝜋𝑛 𝜆⁄  is the wave number of the incident light, n = 1.33, 𝜆 is the source 
light wavelength, and 𝐷(𝒓) ≈ 𝑣/3µ𝑠
′ (𝒓) . 〈∆𝑟2(𝜏)〉 is the mean square displacement of 
the moving scatterers inside the tissue during a time interval τ. A Brownian diffusion 
model  〈∆𝑟2(𝜏)〉 = 6 𝐷𝐵(𝒓)𝜏  is often employed with  𝐷𝐵(𝒓)  denoting the effective 
diffusion coefficient of the moving scatterers (66, 82).  𝐷𝐵(𝒓) depends on the exponential 
decay rate of the measured correlation functions. An α term (ranging from 0 to 1) is 
added to account for the fact that not all scatterers in biological tissues are dynamic, and 
α is defined as the ratio of moving (dynamic) scatterers to total (dynamic and static) 
scatterers. The combined term, 𝛼𝐷𝐵(𝒓), is referred to as the blood flow index (BFI) in 
tissues and its relative change is commonly used to calculate the relative change of blood 
flow (rBF) compared with the baseline BFI before physiological changes. In contrast to 
tissue samples, all scatterers in liquid phantom solutions are considered dynamic with 
𝛼 ≈ 1, and the flow index is thus reported as simply 𝐷𝐵(𝒓). 
The analytical solution of Equation 2.6 with point source impinging upon a semi-
infinite homogeneous medium (Figure 2.2a) is generated as (65):  
𝐺1(𝜌, 𝜏) =
𝑣𝑆0
4𝜋𝐷
(
exp (−𝐾(𝜏)𝑟1)
𝑟1
−
exp (−𝐾(𝜏)𝑟2)
𝑟2
)                                  (2.7) 
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where 𝐾2(𝜏) = 3𝜇𝑠
′𝜇𝑎 + 𝜇𝑠
′ 2𝑘0
2𝛼〈∆𝑟2(𝜏)〉, 𝑟1, 𝑟2 and 𝜌 are the same as in Equation 2.3. 
Consequently, the analytical expression for 𝑔1(𝒓, 𝜏) is derived as: 
𝑔1(𝒓, 𝜏) = (
exp (−𝐾(𝜏)𝑟1)
𝑟1
−
exp (−𝐾(𝜏)𝑟2)
𝑟2
) (
exp (−𝐾(0)𝑟1)
𝑟1
−
exp (−𝐾(0)𝑟2)
𝑟2
)⁄      (2.8) 
Thus the measurements of 𝑔1(𝒓, 𝜏) can be fitted the analytical expression based on 
Equation 2.8 to yield 𝛼𝐷𝐵 , using given values of ρ and values of 𝜇𝑠
′ , 𝜇𝑎  from NIRS 
measurements or literature (65, 66, 83). 
 
2.4 Diffuse Correlation Tomography (DCT) 
The extension of DCS to DCT is comparable to that of DOS to DOT which models 
the propagation of light in diffuse tissue, called “forward problem”, based on Equation 
2.1 and solves the “inverse problem” for spatial distribution of optical parameters 
(e.g., 𝜇𝑎and 𝜇𝑠
′ ) (60, 84). Similarly, the forward problem for DCT is to calculate the 
electric field autocorrelation at the detectors given a geometric model of the optical 
parameters, flow index, and source and detector locations and functionality based on 
Equation 2.6. The inverse problem for DCT is to recover the flow index distribution 
through boundary measurements of autocorrelation function.  
Previous studies involving DCT have used perturbation method to derive the forward 
problem (58-60), however, this method relies on analytical solution of autocorrelation 
function which precludes the transition to complex boundaries and imperfect 
heterogeneities. The finite element framework has been applied in DOT as a numerical 
approximation of partial differential Equation 2.1 for light propagation model and image 
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reconstruction algorithms. This numerical method can resolve the geometry and 
heterogeneity limitations for DOS/DOT (85-87). Because of the mathematical similarity 
of correlation diffusion equation (Equation 2.6) and photon diffusion equation 
(Equation 2.2), the implementation of finite element framework in DCS/DCT has been 
developed (37)，adopting software package NIRFAST (for DOT) (87) as a shortcut.  
Recall Equation 2.6, the term 
1
3
𝜇𝑠
′(𝒓)𝑘0
2𝛼⟨∆𝑟2(𝜏)⟩ can be reshaped as 𝜇𝑎
𝑑(𝒓, 𝜏) =
2𝜇𝑠
′(𝒓)𝑘0
2𝛼𝐷𝐵(𝒓)𝜏, and is considered as “effective dynamic absorption” due to dynamic 
processes on the correlation with 𝜏 (37). DCT is conceptualized as a formulation of DOT 
which computes 𝐺1(𝒓, 𝜏)  instead of photon fluence rate Φ(𝒓, 𝑡) , by updating “static 
absorption” 𝜇𝑎(𝒓)  to 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏) = 𝜇𝑎(𝒓) + 𝜇𝑎
𝑑(𝒓, 𝜏) , and reconstructing 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏) 
instead of 𝜇𝑎(𝒓) only (37).  
 
2.4.1 Forward and Inverse Models 
Chart 1 and Chart 2 illustrate the main commands executed for solving the forward 
and inverse problems respectively in DCT using NIRFAST. A homogeneous background 
tissue volume mesh with assigned initial optical properties of 𝜇𝑎(𝒓) and 𝜇𝑠
′(𝒓) is first 
generated in the forward solution (see Chart 1). All S-D pairs corresponding to the actual 
or simulated scanning of ncDCT probe are placed on the surface of the background mesh. 
However, only those with valid links between sources and detectors are configured as 
effective pairs for image reconstruction. For simulations, an anomaly region (mimicking 
a tumor) inside the background volume mesh is defined and assigned a BFI contrast 
relative to the surrounding background. Based on the designed distributions of BFIs, 
𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏) is updated for each voxel inside the entire tissue volume within a certain 
20 
 
range of 𝜏. The autocorrelation functions 𝐺1(𝒓, 𝜏) for multiple τ values from all effective 
S-D pairs are then calculated by running the forward model. The boundary BFI data at all 
effective S-D pairs are then extracted by fitting 𝐺1(𝒓, 𝜏) to the analytical expression of 
Equation 2.7 under semi-infinite homogeneous geometry.  
 
 
Chart 1: Flowchart outlining the sequence and commands used in the modified 
NIRFAST to generate a forward model for ncDCT. 
 
Solving the inverse problem for image reconstruction is conducted on a second mesh 
with a coarse finite element division (pixel basis) (87, 88) (see Chart 2). Initial values of 
background BFI and optical properties (𝜇𝑎(𝒓) and 𝜇𝑠
′(𝒓)), along with the selected  𝜏 are 
Generate a homogeneous mesh and  
assign 𝜇𝑎 𝒓 and 𝜇𝑠′ 𝒓
Assign BFI 𝒓 for background and anomaly by
updating 𝜇𝑎 𝒓  t  𝜇𝑎
𝑡𝑜𝑡𝑎𝑙 𝒓, 𝜏
Assign valid source and detector pairs
             m  e to calculate boundary 𝐺1 𝒓, 𝜏
Save boundary data of 𝐺1 𝒓, 0 and BFI 𝒓
Define anomaly region
Generate 
Mesh
Calculate for 
Multiple  
Save Data
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assigned to generate a homogeneous inverse mesh. The simulated or measured boundary 
BFI data are converted to  𝑔1(𝒓, 𝜏) at the selected τ using the semi-infinite analytical 
expression of Equation 2.8 (67, 83, 89, 90), and further converted to 𝐺1(𝒓, 𝜏)  by 
multiplying with 𝐺1(𝒓, 0). The boundary 𝐺1(𝒓, 𝜏) functions are then input into the inverse 
model to reconstruct the 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏) distribution inside the entire tissue volume. The BFI 
distributions are finally extracted through the definition of 𝜇𝑎
𝑑(𝒓, 𝜏) . Note that even 
though we can reconstruct 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏)  distribution directly from the simulated or 
measured boundary 𝐺1(𝒓, 𝜏) data, we chose to extract boundary BFI values first and then 
convert them back to 𝐺1(𝒓, 𝜏)  for image reconstruction. This seemingly redundant 
procedure is yet essential for the normalization of BFIs in real measurements (see 
Chapter 5.2.3) as well as reducing the noise influence on the measured 𝐺1(𝒓, 𝜏). 
 
2.4.2 Noise Model for DCT 
To evaluate noise influence on image reconstruction through simulations, randomized 
noise varying at different τ are generated based on a noise model originally derived for 
DCS (83, 91). The noise level depends on the detected photon count rate (i.e., light 
intensity) at each S-D pair, which is estimated using the light intensity detected from in 
vivo tissues (e.g., breast tissue). This noise is applied to the simulated 𝑔2(𝒓, 𝜏) curves. 
Multiple 𝑔2(𝒓, 𝜏) curves with noise are generated for each S-D pair and then averaged to 
improve the signal-to-noise ratio. This simulation mimics our in vivo measurements and 
data averaging process. Finally, 𝑔2(𝒓, 𝜏)  curves are converted to 𝐺1(𝒓, 𝜏)  to generate 
boundary BFI data.  
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Chart 2: Flowchart outlining the sequence and commands used in the modified 
NIRFAST to solve DCT inverse problem. 
 
  
Extract     (𝒓) distribution 
from 𝜇𝑎
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CHAPTER 3 NONCONTACT DIFFUSE CORRELATION TOMOGRAPHY 
(NCDCT) SYSTEM 
 
3.1 Introduction 
Most DCS systems employ contact-based interaction with the sample. However, in 
tissues, contact measurements can promote hemodynamic variations induced by probe 
compression or disturbing sensitive areas. Our lab has recently developed a noncontact 
DCS system that uses a lens-focusing technique to avoid the contact influence (89, 92). 
The probing depth of the noncontact DCS measurement was fixed due to the single 
source-detector (S-D) separation design. To further extend the DCS technique to 
tomographic imaging, an ncDCT system has recently been developed. The ncDCT probe 
has multiple S-D measurement pairs (10-30 mm S-D separations) and the system 
employs a motorized stage for automatic and precise scanning over the region of interest 
(ROI) (37). In addition, the finite-element-method based facilitation of DCT image 
reconstruction as mentioned above enables blood flow imaging on arbitrary boundary 
geometries. Finally, validation efforts have been made including computer simulations 
and phantom tests. The unique noncontact imaging system remedies many of the 
concerns mentioned at beginning of the thesis (Chapter 1.3). 
In this chapter, the ncDCT system instrumentation is first presented in Chapter 3.2. 
Chapter 3.3 describes the procedures to perform blood flow imaging, which includes 
ncDCT scanning (Chapter 3.3.1) and FD NIRS measurements (Chapter 3.3.2). To 
validate the imaging capability of the ncDCT system, computer simulations and tumor-
like phantom experiments with varied flow contrasts are provided based on a simple slab-
shaped tissue boundary (i.e., semi-infinite geometry) (Chapter 3.4) (37). Since liquid 
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(Intralipid solution) and solid phantoms (silicone) are commonly used in instrument 
calibration/characterization and algorithm validation, the fabrication procedures for 
phantoms are provided at the end of this section (Chapter 3.5).      
 
3.2 ncDCT Instrumentation 
Extending DCS to DCT attaches the burden of collecting many boundary 
measurements. As such, our noncontact probe was upgraded to have two identical laser 
source paths and one detector path configured in a linear array (Figure 3.1c). In each 
source path, output from a multimode source fiber (WF200/220/245, CeramOptec, MA, 
USA) connected to a laser (825 nm) on the DCS instrument is projected onto the tissue 
through lenses (Figure 3.1a). Fifteen single-mode detector fibers (SM800-5.6-125, 
Fibercore, CA, USA) are equally arranged in a 7 mm line to cover a 20 mm range 
through the magnification of lenses (Figure 3.1c). The S-D separations vary from 10 to 
30 mm, thus enabling up to ~15 mm penetration depth (37). Two long coherence lasers at 
825 nm (coherence length >5 m, CrystaLaser, NV, USA) emit light to tissue through 
individual source paths, alternatively. The photons traveling through the tissue sample are 
collected by the detector array of 15 avalanche photodiodes (APD, Perkin Elmer, Canada) 
through the detector path. A multi-channel autocorrelator (Correlator.com, NJ, USA) 
takes the APD outputs and calculates 15 intensity correlation functions simultaneously 
(Figure 3.2a). A motorized stage (CR1-Z7, Thorlabs, NJ, USA) is integrated into the 
optical system which rotates the ncDCT probe around the nipple for scanning a ROI on 
the breast surface (Figure 3.1a). A linear stage (5236A16, McMASTER-CARR, IL, USA) 
and a custom-made rotational platform were used to manually align the axis of probe 
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head at the center of ROI and perpendicular approximately to the breast tissue surface 
(Figure 3.1a). The outcomes from this scanning are the boundary data of intensity 
autocorrelation functions collected at hundreds of S-D pairs on the ROI. 
 
Figure 5 
Figure 3.1: The schematic diagram of ncDCT scanning system. (a) A motorized 
rotational stage was used to scan over a representative ROI on the breast and the rotation 
axis was aligned through the nipple; (b) During scanning procedure, the source and 
detector rays were perpendicular to the breast surface and rotationally scanned around the 
nipple to cover the tumor bearing ROI; (c) Fifteen single-mode detector fibers were 
equally projected onto breast surface to cover a 2 cm range while two multimode fibers 
were projected onto two sides of the linear arrays, enabling S-D separations to span from 
1cm to 3 cm. 
 
 
3.3 Blood Flow Imaging Protocols 
3.3.1 ncDCT Scanning 
To demonstrate the scanning protocol for 3-D blood flow imaging in breast tissue, a 
plastic mannequin is placed on the bed to mimic patients lying in a supine position 
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(Figure 3.2b). A red mark made on the mannequin breast surface indicates a tumor 
beneath the skin surface. The rotation axis in the ncDCT probe (Figure 3.1a) is first 
aligned with breast nipple. The probe is then rotated to the top of the red mark and 
adjusted the working distance and projection angle to make the two source rays 
approximately perpendicular to the mannequin breast surface. In order to scan over the 
ROI, the probe is rotated back to the first scanning position and then scans certain 
degrees over a ROI through multiple steps with a 3-degree increment per step. The first 
and last scanning steps cover healthy breast tissue and the middle step is usually on top of 
the lesion mark. Total scanning time was ~25 minutes with 60 s sampling time per step at 
1 Hz DCS sampling rate for each laser source. During the scanning process, two 
projected source pairs at the first and last steps are marked on the breast surface using a 
marker pen.  
 
3.3.2 Commercial 3-D Camera Scanning 
After ncDCT probe scanning, a commercial 3-D camera (NextEngine, CA, USA) is 
used to take the surface geometry of the mannequin breast with source and rotation center 
marks. The working distance is ~17 inch from breast surface, the field of view (FOV) is 
10  13 (Figure 3.2b), and the total acquisition time is ~5 minutes. After that, the 
mannequin is removed and a small foam pad perpendicular to the rotation axis is attached 
to ncDCT probe as a reference plane (RP) (Figure 3.2c). The 3-D camera is used to take 
an image of the RP to co-register the two coordinate systems: ncDCT system and 3-D 
camera, which enables the alignment of the scanned source and detector locations onto 
the breast-shaped mesh. The sequence of taking RP image by 3-D camera is after all 
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measurements in in vivo measurement due to busy clinical workflow and it is described in 
later chapter (Chapter 5.2.2). 
 
 
Figure 6 
Figure 3.2: (a) Photo of the combined ncDCT imaging system and a commercial 
frequency-domain tissue oximeter for tissue optical properties measurement. (b) The 
breast surface with source marks was imaged by the 3-D camera. (c) After the mannequin 
was removed, a small foam pad was attached to the DCS scanner. The 3-D camera took 
another image to include the small foam pad whose surface (RP) was adjusted 
perpendicularly to the rotation axis. The RP was used for the co-registration of two 
coordinates: 3-D camera and ncDCT system. 
 
 
 
16 Channel 
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3.3.3 Frequency-domain NIRS Measurements  
Following the ncDCT measurement, a commercial FD tissue oximeter (Imagent, ISS, 
IL, USA) (71) was used to measure 𝜇𝑠
′  and 𝜇𝑎  of the breast tissue. The Imagent 
instrument includes 110 MHz modulated sources at 4-wavelength (690, 750, 780, and 
830 nm), photomultiplier tubes, and desktop computer control, which ultimately 
calculates tissue optical properties (µa and µs’) (Figure 3.2a). Source and detector fibers 
are embedded in a black flexible probe and the probe is gently placed on the skin surface 
to measurement breast tissue optical properties at certain positions. The measurement 
usually takes ~ 5 minutes.   
 
3.4 ncDCT Validation Results 
In this subsection, initial validation work including computer simulations and 
phantom experiments on slab-shaped geometry with linear probe scanning were 
performed to evaluate the accuracy of our ncDCT system. To test our theoretical DCT 
technique, computer simulation was first conducted in homogeneous situation (i.e., no 
anomaly) to evaluate the forward solution (Chapter 3.4.1). Computer simulations and 
phantom experiments embodied recovery of anomaly flow contrasts were performed to 
further evaluate the inverse solution (Chapter 3.4.2). Background optical properties 
mismatch was also induced in computer simulations and phantom experiments to 
evaluate their crosstalk on reconstructed flow contrasts (Chapter 3.4.3). 
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3.4.1 Forward Solution Validation  
A slab mesh simulating liquid phantom solution [dimension (mm): 90 (H)   90 (W) 
  35 (D)] was first generated in SolidWorks® (Dassault Systemes, MA, USA) and then 
segmented into finite elements using ANSYS
®
 (ANSYS, PA, USA). A total of 73949 
nodes were created with node distances of 2 mm. The segmented mesh nodes and 
elements information were then input into MATLAB
®
 (MathWorks, MA, USA) to 
generate all mesh files needed for the simulations with NIRFAST. Optical properties 
were set throughout at 𝜇𝑠
′ = 8.00 cm-1 and 𝜇𝑎 = 0.045 cm
-1
 close to breast tissue values 
(93). The blood flow index (BFI) for the background was set as 1  10-8 cm2/s close to 
Intralipid phantom values (58, 67). The noncontact probe scanned linearly (mimicked in 
simulation) across the ROI in 15 steps with an increment of 4 mm/step generating a 
scanning area of 40 mm   56 mm and 450 (15 steps   15 APDs   2 sources) effective S-
D pairs (Figure 3.3). The forward solution (i.e., 𝐺1(𝒓, 𝜏)) was calculated by the modified 
NIRFAST with 𝜏 from 0 to 8   10-6 s. Minimal simulation aberrations over the measured 
ROI (1% mean discrepancy and 1.45% standard deviation) were observed between BFI 
extracted using the established semi-infinite analytical solution (37) in Equation 2.6 
(Chapter 2) and the assigned BFI. The computer simulation validated the algorithm for 
calculating forward solution using Equation 2.6 based on NIRFAST.  
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Figure 7 
Figure 3.3: Illustration of the ncDCT system linearly scanning across the ROI of liquid 
phantom surface with a pump-connected cylindrical tube placed inside the tank.  
 
3.4.2 Inverse Solution Validation 
Computer Simulations. A cylindrical tube-shaped anomaly [dimension (mm): 13 
(Dia.)   80 (L)] was inserted beneath the middle of the ROI with a depth of 12.5 mm 
from the tube center to the ROI surface (Figure 3.3). The 𝜇𝑎      𝜇𝑠
′  inside the anomaly 
were matched to the background tissue. The attributed anomaly BFI was increased from 
0-fold to 20-fold at 4-fold increment per step. Reconstruction was conducted on the same 
mesh with a pixel basis of 20  20  25 (node number: 11,025) and at selected delay 
time 𝜏1 = 3.2   10
-6
 s. Due to limited ROI dimensions along the tube, only partial 
anomaly reconstruction was possible (Figure 3.4a). For percentage flow change 
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31 
 
comparison, the reconstructed anomaly peak flow value was normalized to the averaged 
step differences of BFI. Both the shape (Figure 3.4a) and relative anomaly peak flow 
contrast changes (Figure 3.4b) were well reconstructed (regression slope = 1.00, R
2
 = 
1.00 and p < 10
-5
). The anomaly was extracted with the full width half-maximum 
(FWHM) criterion (94) on the reconstructed DCT image. The averaged BFI of the 
reconstructed anomaly was computed by averaging the BFIs within the anomaly. An 
excellent linear relationship was also observed between the reconstructed and assigned 
percentage flow changes (data are not shown; regression slope = 1.00, R
2
 = 1.00 and p < 
10
-5
).  
Phantom Experiments. A background of tissue-like liquid phantom was placed in an 
aquarium and a pump-connected cylindrical tube anomaly was filled with liquid and 
small pieces of solid phantom (Figure 3.3). The tissue-like liquid phantom (Chapter 
3.5.1) was comprised of Intralipid, distilled water and India ink, and has been used 
extensively for DCS calibrations (92). Intralipid particles (Fresenius Kabi, Sweden) 
provide control of scattering (𝜇𝑠
′ ) and Brownian motion (𝐷𝐵 ; 𝛼 ≈ 1) while India ink 
controls absorption ( 𝜇𝑎 ). We set 𝜇𝑠
′ = 8.10 𝑐𝑚−1  and 𝜇𝑎 = 0.044𝑐𝑚
−1  while 
quantifying them with Imagent (Figure 3.2a). To create flow index contrasts against the 
background, a clear plastic tube [dimension (mm): 13.5 (Dia.)   80 (L)] with a very thin 
wall (0.35 mm) was placed at ~12.5 mm (tube center to ROI surface) into the background 
liquid phantom (Figure 3.3). The tube was mostly filled with small pieces of solid 
phantom (𝜇𝑠
′ = 10.00 cm-1 and 𝜇𝑎 = 0.10 cm
-1
) to randomize pumped particle motions as 
Brownian motion and generate a diffusive circumstance for photons. Solid phantoms 
were comprised of titanium dioxide, silicon and carbon black (Chapter 3.5.2). A 
32 
 
peristaltic pump (HV-77201-60, Cole Parmer, IL, USA) connected in series with a 
hydraulic capacitor that damped fluid pulsations was employed to create step increases in 
steady flow from 0 to 20 ml/min at 4 ml/min increments within the tube. The noncontact 
probe was first calibrated to the homogeneous liquid phantom region. The scanning 
procedure was linear as assumed in simulations. Total scanning time was ~20 minutes 
with 60 s sampling time per step at 0.5 Hz DCS sampling rate for each laser. We used 
identical reconstruction parameters as the simulation including slab mesh and delay time 
𝜏1  with the exception of a median filter application. This latter addition assisted in 
stabilizing inherent experimental noise not encountered in the ideal simulation (87). The 
relationship between macro pumped flow (unit: ml/min) and micro particle motion (𝛼𝐷𝐵 
unit: cm
2
/s) is complicated, but was confirmed linear (95). For this case the assigned flow 
represents the macro flow (pump speed) rather than DCS indices. Figure 3.4d presented 
relative macro and micro flow changes using the same way as in simulations. A tube-
shaped anomaly was clearly observed after image reconstruction (Figure 3.4c). The 
reconstructed flow indices accurately captured the flow changes in the tube when 
quantified with the peak value (Figure 3.4d; linear regression slope = 0.97, R
2
 = 1.00 and 
p < 10
-5
) and with the mean of extracted anomaly (data are not shown; linear regression 
slope = 0.99, R
2
 = 0.96 and p < 10
-3
).  
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Figure 8 
Figure 3.4: Results of computer simulation and phantom experiment utilizing a 
homogeneous slab background and internally placed tube-shaped anomaly of varied flow 
contrast. The reconstructed anomaly from the last step with highest flow contrast is 
shown (a) 3-D overlaid on the assigned anomaly and (c) in the phantom experiment. Both 
(b) and (d) show a linear relationship between the assigned anomaly and reconstructed 
flow indices expressed as ratios of relative changes respectively in the simulation and 
phantom experiment. 3-D data are displayed with open source visualization software 
PareView (Kitware, NY, USA). 
 
 
3.4.3 Influence of Optical Property Mismatch on ncDCT Accuracy  
We note that no optical property mismatch between anomaly and background was 
induced, i.e., ∆𝜇𝑠
′ = 0 and ∆𝜇𝑎 = 0, in the computer simulations and phantom tests 
performed earlier. However, our previous published studies have showed that the 
mismatch of  𝜇𝑎  and 𝜇𝑠
′  can result errors in estimating DCS flow index (67). In the 
0 100 200 300 400 500 600
0
200
400
600
x: relative change of assigned BFI (%)
y
: 
re
la
ti
v
e
 c
h
a
n
g
e
 o
f 
B
F
I 
(%
)
0
y = 1.00x + 13.56
R2 = 1.00, p < 10-5 20
16
12
8
4
Assigned Contrast
(fold)
0 200 400 600
0
200
400
600
y
: 
re
la
ti
v
e
 c
h
a
n
g
e
 o
f 
B
F
I,
 (
%
)
x: relative change of pump speed, (%)
0
y = 0.97x + 20.58
R2 = 1.00, p < 10-5
Pump speed
(ml/min)
16
20
12
8
4
(b)
(d)
34 
 
following computer simulation and phantom experiments, the influence of 𝜇𝑎  and 
𝜇𝑠
′mismatch on ncDCT flow contrast reconstruction is presented below. 
The Influence of 𝝁𝒔
′  on DCT. Recall that 𝜇𝑠
′ = 8.00 cm-1 and 𝜇𝑎 = 0.045 cm
-1
 in the 
previous experiments. In this computer simulation, the 𝜇𝑠
′  of background was changed to 
3.2 cm
-1
 to generate a 250% 𝜇𝑠
′  contrast (8.0/3.2) in the anomaly. For the phantom 
experiment, the new background 𝜇𝑠
′  was accomplished by adjusting the concentration of 
Intralipid and was measured/verified by Imagent. Flow indices were reconstructed under 
two experimental conditions: (1) assign homogenous optical properties in the forward 
and inverse solutions (𝜇𝑎 = 0.045 𝑐𝑚
−1 , 𝜇𝑠
′ = 8.0 𝑐𝑚−1 ) for both the anomaly and 
background; (2) assign separate property values for the anomaly (𝜇𝑎 = 0.045 𝑐𝑚
−1, 𝜇𝑠
′ =
8.0 𝑐𝑚−1) and background (𝜇𝑎 = 0.045 𝑐𝑚
−1, 𝜇𝑠
′ = 3.2 𝑐𝑚−1) in the forward solution 
and use a homogenous mesh ( 𝜇𝑎 = 0.045 𝑐𝑚
−1, 𝜇𝑠
′ = 3.2 𝑐𝑚−1 ) for image 
reconstruction. The differences in the reconstructed flow index contrasts between the two 
conditions were compared.     
Figure 3.5 shows the computer simulation results. In Figure 3.5a, the reconstructed 
flow index contrasts under Condition #2 were normalized to those under Condition #1 for 
comparisons. The underestimations of µs
′  contrasts under Condition #2 (i.e., assuming 
𝜇𝑠
′ = 3.2 𝑐𝑚−1  in the anomaly) resulted in similar overestimations (ratios) of flow 
contrasts at different flow levels. However, the relative changes of flow contrasts over the 
large range of flow variations were not influenced by the incorrect assumptions of 𝜇𝑠
′  
(Figure 3.5b). Figure 3.6 shows the phantom experimental results, which are very 
similar to those in computer simulations (Figure 3.5). 
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Figure 9 
Figure 3.5: Computer simulation results. (a) The underestimations of 𝜇𝑠
′  in the anomaly 
generated the overestimations of flow contrasts (red bars). (b) Linear relationships 
between the assigned and reconstructed flow index contrasts expressed as ratios of 
relative changes reconstructed under Condition #1 (blue dots) and Condition #2 (red dots).   
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Figure 10 
Figure 3.6: Phantom experimental results. (a) The underestimations of 𝜇𝑠
′  in the anomaly 
generated the overestimations of flow contrasts (red bars). (b) Linear relationships 
between the assigned and reconstructed flow index contrasts expressed as ratios of 
relative changes reconstructed under Condition #1 (blue dots) and Condition #2 (red dots).   
 
The Influence of 𝛍𝐚 on DCT. Similar to the evaluation of 𝜇𝑠
′  influence, we use 
computer simulations to set up 2- and 3-fold contrasts of anomaly 𝜇𝑎  with the 
background. In the reconstruction, we ignored the variations of 𝜇𝑎  in the anomaly 
(0.09 cm−1  and 0.135 cm−1 ) and reconstructed flow contrasts using the background 
optical properties (𝜇𝑎 = 0.045 𝑐𝑚
−1 and 𝜇𝑠
′ = 8.0 𝑐𝑚−1). Reconstructed flow contrasts 
were normalized to the homogeneous case (i.e., no 𝜇𝑎  anomaly/background contrast). 
Figure 3.7 shows that the underestimations of 𝜇𝑎  contrasts resulted in the 
(a)
(b)
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underestimations in flow contrasts (Figure 3.7a). However, the relative changes of flow 
index contrasts over the large range of flow variations were not influenced by the 
incorrect assumptions of 𝜇𝑎 (Figure 3.7b). 
 
Figure 11 
Figure 3.7: Computer simulation results. (a) The underestimations of 𝜇𝑎generated the 
underestimations of flow contrasts (green and red bars). (b) Linear relationships between 
the assigned and reconstructed flow indices expressed as ratios of relative changes 
reconstructed using different 𝜇𝑎 values. 
 
In summary, inaccurate µs’ assumptions resulted in much greater flow index errors 
than inaccurate µa assumptions. Specifically, ~250% underestimation of µs’ led to 
245 ± 2% overestimation of flow indices in simulations and 297 ± 40% overestimations 
in phantom experiments, whereas 200% to 300% underestimation of µa led to 11.5 ± 2% 
to 26 ± 3%  underestimations of flow indices, respectively. All these results are 
(a)
(b)
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consistent with our previous studies using DCS (67, 83). Nevertheless, the relative 
changes of flow index contrasts over the large range of flow variations can be accurately 
reconstructed even with the incorrect assumptions of optical properties.  
 
3.5 Discussion and Conclusions 
In this chapter, the instrumentation of our newly developed ncDCT system for 3-D 
blood flow contrast imaging was reported. A plastic mannequin was used to demonstrate 
the blood flow imaging protocol for breast tumor detection. The procedures to collect 
breast boundary blood flow index and surface geometry were described in detail. 
We further validated the ncDCT system for the flow contrast imaging using computer 
simulations and tissue phantom tests. The results indicated that the cylindrical tube-
shaped anomaly inside homogenous background tissue can be clearly reconstructed and 
high correlation was observed between the reconstructed and assigned anomaly flow 
contrast.  We also found inaccurate µs’ assumptions resulted in much greater flow index 
contrast errors than inaccurate µa. These findings suggest that investigations involving 
significant µa and µs’ changes should concurrently measure flow indices and optical 
properties for avoiding over/underestimation of flow indices.  However, the relative 
changes of reconstructed flow index contrasts can be accurately reconstructed even with 
the incorrect assumptions of optical properties.  
In conclusion, a novel ncDCT system was built for blood flow contrast imaging in 
deep biological tissue. The imaging capability was validated through both computer 
simulations and phantom experiments based on slab-shaped geometry with linear 
scanning protocol. 
39 
 
3.6 APPENDIX: Recipes for Making Tissue-like Phantoms 
Optical phantoms are constructed to mimic the optical absorption and scattering, and 
particle Brownian motion (only liquid phantom) of tissue. In our lab, liquid and solid 
phantoms are made to provide a tissue model for probe calibrations, titration experiments 
and testing image reconstruction algorithms. 
 
3.6.1 Liquid Phantom Creation: Intralipid 
In our lab, distilled water, India ink (Black India 44201, Higgins, MA) and Intralipid 
(30%, Fresenius Kabi, Uppsala, Sweden) are utilized in constructing liquid phantoms 
which provide a homogeneous tissue model (41, 67, 92). India ink is used to manipulate 
µa (λ) and has minimal influence on phantom scattering. The µa (λ) values at certain 
wavelengths are calculated based on the concentration of India ink. Intralipid is used to 
control µs’ (λ) via changing its concentration and provides particle Brownian motion (DB; 
α ≈ 1). The absorption of the lipid particles is negligible. Distilled water contributes little 
to both absorption and scattering, allowing for larger phantom volumes to facilitate 
satisfying the semi-infinite geometry model. Based on the desired values of µa (λ) and µs’ 
(λ) for the phantom, the liquid phantom creation procedure is given bellow.  
Calculation of Ink Volumes for Desired Absorptions. The India ink needs to be 
diluted to 10% concentration (or lower concentration, which depends on the volume of 
the aquarium holding liquid phantom), due to the very high absorption of pure India ink. 
The absorbance of the 10% ink solution should be measured with the spectrometer 
(Beckman Coulter, CA, USA). Since the 10% ink solution is not within the measurable 
range of our spectrometer, it is further diluted to 0.025% concentration. Multiple samples 
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of 0.025% ink solution are measured by spectrometer at 690, 750, 780 and 830 nm 
(matching the Imagent source wavelengths) and the measured absorbance is further 
converted to absorption coefficient by the equation: 𝜇𝑎(𝜆) =   (10)  𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝜆) 
(9). This 𝜇𝑎(𝜆)  is for 0.025% concentration ink solution. Therefore, one needs to 
multiply 𝜇𝑎(𝜆) by a factor of 400 for the absorption coefficient of 10% ink solution 
(𝜇𝑎  𝑖𝑛𝑘(𝜆)). As Intralipid is primarily comprised of water, it is assumed to have an 
absorption coefficient equivalent to water (𝜇𝑎  𝑤𝑎𝑡𝑒𝑟= 𝜇𝑎  𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑). The 𝜇𝑎  𝑤𝑎𝑡𝑒𝑟(𝜆) values 
at those wavelengths can be obtained from the literature (96). Knowing the desired value 
of absorption coefficient for the phantom (𝜇𝑎  𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝜆) ) and the volume of total 
phantom solution (𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚), the volume of 10% ink solution (Vink) can be determined 
as: 
𝜇𝑎  𝑤𝑎𝑡𝑒𝑟(𝜆)  (𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 − 𝑉𝑖𝑛𝑘) + 𝜇𝑎  𝑖𝑛𝑘(𝜆)  𝑉𝑖𝑛𝑘 = 𝜇𝑎  𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝜆)  𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚     (3.1) 
The volume of distilled water is simply the remaining volume to be filled (i.e., 𝑉𝑤𝑎𝑡𝑒𝑟 =
𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚 −𝑉𝑖𝑛𝑘 − 𝑉𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑).  
For the titration experiment, 10% ink solution is added to the phantom at each step to 
increase 𝜇𝑎  𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝜆). The volume of 10% ink solution to be added is described by the 
following equation: 
𝜇𝑎
𝑏𝑒𝑓𝑜𝑟𝑒
phantom
 (λ) × 𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚
𝑏𝑒𝑓𝑜𝑟𝑒
 + 𝜇𝑎
ink
 (λ) × 𝑉𝑖𝑛𝑘
𝑎𝑑𝑑 = 𝜇𝑎
𝑎𝑓𝑡𝑒𝑟
phantom
(λ) × (𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚
𝑎𝑓𝑡𝑒𝑟
+ 𝑉𝑖𝑛𝑘
𝑎𝑑𝑑) 
(3.2) 
where the “before” and “after” indicate the procedure of adding ink solution.  
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Calculation of Intralipid Volume for Desired Scattering. According to van 
Staveren’s Mie theory approximation (97), 𝜇𝑠
′(𝜆)  of 10% Intralipid is given by the 
equations:  
𝜇𝑠 = 2.54  10
9  𝜆−2.4                                         (3.3) 
𝑔 = 1.1 − 0.58  10−3𝜆                                           (3.4) 
𝜇𝑠
′ = 𝜇𝑠(1 − 𝑔)                                                  (3.5) 
where λ is in [nm] and  𝜇𝑠 and 𝜇𝑠
′  are in [cm
-1
]. The 𝜇𝑠
′(𝜆) of 10% Intralipid multiplies a 
factor of three can generate  𝜇𝑠
′(𝜆) of 30% Intralipid (denoted as 𝜇𝑠 𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑
′ (𝜆)). As 
there are expected to be no contributions to the phantom scattering by the 10% ink 
solution or distilled water, both are ignored in calculation. Knowing the desired value of 
reduced scattering coefficient (𝜇𝑠 𝑝ℎ𝑎𝑛𝑡𝑜𝑚
′ (𝜆)), the volume of 30% Intralipid to be used 
can be calculated by equation: 
𝜇𝑠 𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑
′ (𝜆)   𝑉𝐼𝑛𝑡𝑟𝑎𝑙𝑖𝑝𝑖𝑑 = 𝜇𝑠 𝑝ℎ𝑎𝑛𝑡𝑜𝑚
′ (𝜆)   𝑉𝑝ℎ𝑎𝑛𝑡𝑜𝑚            (3.6) 
 
3.6.2 Solid Phantom Creation: Silicone 
Solid phantoms are useful for simulating tissue-like geometry and do not deteriorate 
as the liquid phantom. Among the choices of solid phantoms, there are mainly three kinds 
of phantom matrix, including gelatin, resin and room temperature vulcanization (RTV) 
silicone (98, 99). The gelatin (also called agar) phantom is the cheapest, however, it is the 
least usable and can become fragile and crumble under applied stress. Both of the other 
two phantoms are stiff and stable. Their fabrication procedures and functions are very 
similar. Previous study showed by reducing the hardener in RTV silicone phantom, 
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stiffness of the phantom can be reduced, shaping this material into more biologically 
relevant configuration (100). In our lab, the RTV silicone phantom is used. 
Soft rubber texture similar to stiff tissue phantom can be made out of silicone and 
used for years.  Titanium dioxide (TiO2) and carbon black are added to provide scattering 
and absorption contrast. Careful preparation is required for prevention of bubbles and 
proper curing. A recipe and fabrication procedure is listed below. 
 
 
Figure 12 
Figure 3.8: Photographs of (a) an empty mold that four facets can be disassembled and 
(b) a cured silicone phantom 
 
RTV Silicone Phantom Recipe 
Ingredients: 1. Silicone and hardener (RTV-615 silicone optical 2-part flow clear RTV   
SS4120-1P primer required, Circuit Specialists Inc, Mesa, AZ)  
2. Scatterer (Titanium (IV) Oxide, Alfa Aesar, Chicago, IL)  
3. Absorber (Carbon Black (99.9+% pure), Alfa Aesar, Chicago, IL) 
 
(a) (b)
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Tools: 1. Mold (Figure 3.8a, do not use silicone or rubber molds) 
2. Mixing bowl  
3. Mortar and pestle for mixing TiO2 and carbon black  
4. Spatula for mixing silicone and hardener 
5. Blender with at least a 0.25 HP motor and a 1 liter container  
6. Balance (scales) with at least 0.01g mass resolution and weighing paper 
7. Rubber gloves 
8. Dust mask 
9. Tight-lidded containers, suitable for long-term storage 
10. Hair dryer 
 
Assembly Sequence: 
Since the amount of carbon black (CB) needed is tiny compared with TiO2, we 
usually first make sufficient amount of 1:100 CB/TiO2 mixture and then mix the CB/TiO2 
mixture with pure TiO2 to achieve the expected optical properties.  
1. Make the 1:100 carbon black (CB) / TiO2 mixture. 
1) Weigh out 1.8 g TiO2 and 0.2 g CB to make 1: 9 CB / TiO2 mixture and mix them 
completely with mortar and pestle. Then transfer the mixture to a container. 
2) Weigh 0.1∗N g mixture made in 1) and 0.91∗N g pure TiO2 to make 1:100 CB / TiO2 
mixture. The mixture should be completely mixed with clean mortar and pestle. Then 
transfer the final mixture to a container and label it. 
Because the exact ratio of CB to TiO2 in a mixture is hard to control or determine, 
the absorptivity of each mixture must be found. (Since carbon black is very “sticky” 
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and very little is used, it is difficult to account for all the carbon black lost to the 
insides of the mortar/pestle, etc.)   
2. Determine the absorptivity of the mixture in units of cm-1∙g-1∙306 g silicone kit. 
1) Make a test silicone phantom with certain amounts of 1:100 CB/TiO2 mixture and 
pure TiO2. According to the experience, ~ 0.0446 g 1:100 CB/TiO2 mixture and 
~0.4177 g pure TiO2 make 𝜇𝑎 ≈ 0.061 𝑐𝑚
−1 and 𝜇𝑠
′ ≈ 10.3 𝑐𝑚−1.  
2) Measure the optical properties 𝜇𝑎  and 𝜇𝑠
′  with the commercial frequency-domain 
tissue oximeter. Measured 𝜇𝑎 subtract 0.01 cm
-1
 is the 𝜇𝑎 contributed by CB at 750 
nm wavelength (the 𝜇𝑎 of silicone is constant at ~0.01 cm
-1
). 
3) Divide the mass of the mixture used by the corrected absorption coefficient. This is 
the absorptivity of the CB/TiO2 mixture in units of cm
-1
∙g
-1
∙306 g silicone kit. 
𝑎𝐶𝐵/𝑇𝑖𝑂2 =
(𝜇𝑎−0.01)
𝑀𝐶𝐵/𝑇𝑖𝑂2
                                                 (3.7) 
where 𝑎𝐶𝐵/𝑇𝑖𝑂2  is the absorptivity, 𝜇𝑎  is the measured absorption coefficient, and 
𝑀𝐶𝐵/𝑇𝑖𝑂2 is the mass of 1:100 CB/TiO2 mixture used to make the test phantom. Here 
it is assumed that one 306 g silicone kit was used to make the phantom. 
3. Make the solid phantom with target optical property 
1) Calculate the mass of CB/TiO2 mixture needed according to the targeted 𝜇𝑎 of the 
phantom:  
𝑀𝐶𝐵 𝑇𝑖𝑂2⁄ =
(𝜇𝑎−0.01)
𝑎𝐶𝐵 𝑇𝑖𝑂2⁄
∙ 𝑁𝐾                                            (3.8) 
where 𝜇𝑎  is the expected absorption coefficient, 𝑎𝐶𝐵 𝑇𝑖𝑂2⁄  is the absorptivity of the 
CB/TiO2 mixture measured from the test phantom, and NK is the number of 306 g 
silicone kit used (can be fraction). Previous study using similar CB as absorbing agent 
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has reported the linear relationship between the mass of CB and phantom 𝜇𝑎 under 
𝜇𝑎 = 0.1 cm
-1
(9). 
2) Calculate the mass of TiO2 needed according to the targeted 𝜇𝑠
′  of the phantom. The 
relationship between the mass of TiO2 used and the 𝜇𝑠
′  is roughly 0.024 cm
-1
g
-1
306 g 
silicone kit, at 750 nm wavelength. 
𝑀𝑡𝑜𝑡𝑎𝑙−𝑇𝑖𝑂2 =
𝜇𝑠
′  
0.024
∙ 𝑁𝐾                                           (3.9) 
where 𝑀𝑡𝑜𝑡𝑎𝑙−𝑇𝑖𝑂2is the mass of TiO2, 𝜇𝑠
′  is the targeted 𝜇𝑠
′  and NK is the number of 
306 g silicone kit used. The value, 0.024 is only a rough estimate based on previous 
phantom made with the same TiO2 powder. Then the mass of pure TiO2 added 
besides the CB/TiO2 mixture is:   
𝑀𝑎𝑑𝑑𝑒𝑑−𝑇𝑖𝑂2 = 𝑀𝑡𝑜𝑡𝑎𝑙−𝑇𝑖𝑂2 −𝑀𝐶𝐵 𝑇𝑖𝑂2⁄                        (3.10) 
3) Mix the CB/TiO2 mixture and pure TiO2 powder. 
Mix the new mixture completed in the mixing bowl. Then transfer it to the NK ∙ 
306 g silicone in the blender. Mix them for totally 10 min with 10 sec at each time. 
4) Mix the silicone with hardener. 
First, weigh 
1
10
∙ 𝑁𝐾 ∙ 306 g silicone hardener. It should be noted that reduce the 
amount of hardener may decrease the stiffness of the cured phantom. Then, transfer 
the mixture to a clean mixing bowl after the power and silicone mixture is completely 
cooled off and no bubbles left. The hair dryer on “cool” can be used to blow air on 
the surface of the phantom to break up any bubbles or foam. Slowly add the hardener 
to the silicone. Gently and thoroughly mix them with the spatula. Make sure no air 
bubble is induced. 
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5) Transfer the mixture equally into the phantom mold. Cover the mold with clean sheet 
and let it sit in the room temperature for ~1 day. 
6) After the phantom is cured, disassemble the mold and remove the phantom. Since the 
cured phantom attaches the mold very tightly, it is not easy to remove the phantom 
from the mold. The mold we used is customized that the four facets can be 
disassembled.   
7) Clean the tools. 
Since the silicone is very viscous, it may flow very slowly. It cannot dissolve in 
the water. So to clean the blender, just place the blender bottle upside down in a place 
lined with a plastic bag overnight and most of the silicone may flow away.  
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CHAPTER 4 COMPUTER SIMULATIONS FOR NCDCT OF BREAST TUMORS 
 
4.1 Introduction 
The recently developed ncDCT in our laboratory provides a unique tool for three-
dimensional (3-D) flow imaging of deep tissue (37). Initial validation efforts for the 
innovative ncDCT system have been made using computer simulations and tumor-like 
phantoms on a simple semi-infinite geometry (see Chapter 3). To translate this novel 
technique to clinical use for breast tumor imaging, the imaging ability of arbitrary 
boundaries (e.g., breast shape) is necessary. In this chapter, computer simulations are 
carried out to characterize the performance of ncDCT system for imaging an anomaly 
(tumor) with varied flow contrasts and depths inside the tissue volumes under breast-
shape tissue boundary.  
 
4.2 Computer Simulation Protocols  
We conducted several computer simulations to characterize the performance of 
ncDCT system. The first simulation tested the abilities of ncDCT in recovery of an 
anomaly (tumor) beneath the surfaces of a slab and a female plastic mannequin breast 
(Chapter 4.2.1). The second simulation evaluated the reconstruction accuracies of the 
anomaly with varied depths and flow contrasts in the same plastic mannequin breast. The 
influence of noise on ncDCT image reconstruction was also assessed and compared with 
the results without noise (Chapter 4.2.2). The next simulation applied a priori structural 
knowledge of the anomaly in the inverse mesh to improve the accuracy of flow image 
reconstruction (Chapter 4.2.3). The last simulation evaluated the influence of different 
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delay time τ selection on ncDCT image reconstruction and the optimized τ selection was 
provided (Chapter 4.2.4). 
 
4.2.1 Reconstruction of a Tumor in Slab-shaped and Breast-shaped Tissue Volumes 
To evaluate the reconstruction of an anomaly inside a background tissue volume with 
a simple semi-infinite geometry, a slab volume [dimension (mm): 100 (H)  100 (W)   
40 (D)] was first generated in SolidWorks and then segmented into finite elements using 
ANSYS. A total of 15996 nodes were created with node distances of 3 mm and 6 mm in 
the region of interest (ROI) and the surrounding region, respectively (Figure 4.3a). 
Different mesh resolutions were employed to reduce the total node number while 
maintaining appropriate spatial resolution in the ROI. The segmented mesh nodes and 
elements information were then input into MATLAB to generate all mesh files needed 
for the simulations with NIRFAST. The slab volume mesh represented a healthy 
background tissue volume. A spherical anomaly with a diameter of 10 mm mimicking a 
tumor was then placed at the ROI center and the anomaly centroid location was 7 mm 
beneath the surface of background tissue volume (Figure 4.3a). Optical properties for 
both tumor and background tissues were set homogeneous throughout the entire slab as 
μs’ = 6.00 cm
-1
 and μa = 0.06 cm
-1
. The blood flow indices for the background and 
anomaly were set as 1  10-8 cm2/s and 10  10-8 cm2/s, respectively, resulting in a 10-
fold flow contrast between the tumor and surrounding normal tissues (Figure 4.3c). The 
ncDCT probe with a linear S-D array scanning rotationally over the ROI was simulated 
for 21 steps with 3 degrees per step to collect the boundary data (Figure 4.3a). There 
were totally 42 sources and 315 detectors distributed on the ROI according to the 
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scanning procedure. Thus, 630 (315  2) source-detector (S-D) pairs were effectively 
available and used for image reconstruction. The autocorrelation functions 𝐺1(𝒓, 𝜏) from 
the effective S-D pairs were calculated by the modified NIRFAST software with 𝜏 
ranging from 0 to 3.2  10−5 s (50 consecutive 𝜏 values). Reconstruction was conducted 
on the same mesh with a pixel basis of 20  20  25 and a 𝜏1 = 8.7   10
−6 s. The 𝜏 
selection is discussed in the following section (Chapter 4.2.4). The presenting anomaly 
was extracted with the full width half-maximum (FWHM) criterion (94) on the 
reconstructed DCT image. The averaged BFI and the center location of the reconstructed 
anomaly were computed by averaging the BFIs and node coordinates within the anomaly. 
 
 
Figure 13 
  
Figure 4.1: Procedures converting the breast surface image to a solid breast model. (a) 3-
D surface geometry of mannequin breast and the reference plane (RP) recorded by 3-D 
camera. The lesion mark (red square), three pairs of source marks and the rotation center 
mark can be clearly seen. (b) A bottom plane (BP) parallel to the RP was created and a 3-
D solid breast model was then generated by enclosing the 2-D contour of BP and the 3-D 
breast surface. 
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Figure 14  
Figure 4.2: Alignment of sources and detectors on the surface of solid breast model. (a) 
A scanning plane (SP) perpendicular to the breast surface and crossing the optical rays of 
sources and detectors was first aligned passing through the first pair of source marks (M1 
and M2). (b) Each source or detector path was simplified as a single optical ray 
perpendicular to the straight line across the source marks (M1 to M2). The sources and 
detectors along the optical rays were then projected onto the surface of solid breast model. 
The SP was then rotated around the rotation axis step-by-step with a 3-degree increment 
per step for projecting sources and detectors at all scanning steps. (c) The alignment of all 
scanned source and detector coordinates. 
 
In order to assess the ability of ncDCT for imaging a tumor inside breast, I conducted 
a computer simulation on a female plastic mannequin breast. The surface geometry of the 
mannequin breast with source marks of ncDCT were scanned by a commercial 3-D 
camera, which was further converted to a solid breast tissue volume using SolidWorks 
(Figure 4.1). The scanned source and detector coordinates were then aligned on the 
surface of the solid breast model based on two pairs (at first and last scanning steps) of 
source marks (Figure 4.2). The probe scanning procedure was simulated by SolidWorks. 
Similar to the slab meshing, the solid breast volume was segmented into finite elements 
with node distances of 3 and 6 mm in the ROI and surrounding region. A solid volume 
mesh [largest dimension (mm): 100 (H)  78 (W)  70 (D)] with total nodes of 14717 
was generated for simulations. A spherical tumor with a diameter of 10 mm and a node 
distance of 3 mm was then placed at the ROI center and the tumor centroid location was 
7 mm beneath the breast surface (Figure 4.3e). For comparisons, we assigned the same 
BP
Source Rays
Detector Rays
Rotation Direction
Rotation Axis First Step Marks
Last Step Marks
-L/2     -L/4       0       L/4      L/2
(a) (b)
M1
M2
SP
L
(c)
M1
M2
51 
 
optical properties and BFI contrast as those used in slab-tissue simulation. The boundary 
data were also collected in the same manner over the ROI on the breast surface. Identical 
breast-shaped mesh with a pixel basis of 20  20  30 and 𝜏1 = 8.7   10
−6 were used 
for image reconstruction. 
 
4.2.2 Quantification of Tumor Location and Flow Contrast in the Breast-shaped Tissue 
Volume 
This simulation used the same tumor model in the breast-shaped mesh with the same 
configuration and optical properties as assigned in Chapter 4.2.1 (see Figure 4.3e). The 
tumor was placed beneath the surface of the breast-shaped mesh with varied central 
depths from 7 mm to 15 mm at 1 mm increment per step. It is noted that breast tumors 
with their centroid locations within the sensitive region of diffuse light (i.e., the detected 
penetration depth of NIR light is ~1/2 of the S-D separation (65, 67, 101)) were our most 
interested study population, since more reliable reconstructions can be generated. At each 
depth, the tumor-to-normal flow contrast was increased from 0-fold to 20-fold at 5-fold 
increment per step. The reconstructed tumor depth was characterized as the shortest 
distance from the reconstructed anomaly center to the breast mesh surface. The 
measurement accuracy of ncDCT system was assessed by quantifying the discrepancies 
between the reconstructed and assigned values in tumor central location and flow contrast. 
To evaluate the noise influence on image reconstruction, I added noise on the subsets 
of boundary data collected from the tumor with 10-fold flow contrast throughout all 
varied depths. Forty  𝑔2(𝒓, 𝜏) curves with noises were generated and averaged at each 
effective S-D pair for DCT image reconstruction. 
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4.2.3 Reconstruction with A Priori Knowledge of Tumor Location and Volume 
To improve the reconstruction accuracy of anomaly blood flow contrast, the soft-
constraint method (94, 102-104) in NIRFAST package was tested in this simulation. A 
priori structural information of tumor (i.e., central location and tumor volume) was 
included in the inverse mesh by labeling the nodes in the inverse mesh according to the 
regions of tumor or surrounding tissues. A regularization matrix L was applied to the 
penalty term in the minimization function for DCT inverse problem, which was 
equivalent to applying a Laplacian-type filter to minimize variation within each region.  
Simulations were done with the spherical anomaly (10-fold flow contrast and diameter = 
10 mm) placed at either 7 mm or 15 mm central depth beneath the breast surface and with 
or without noise.  
 
4.2.4 Evaluation of Image Reconstruction Accuracy with Different τ Values 
Previous DCT studies emphasized assigning a selective delay time 𝜏 to each S-D pair 
based on the analytical expression for 𝑔1(𝒓, 𝜏) (Equation 2.6) which relies on simple 
geometry and homogeneous optical properties (60)(59). By contrast, we proposed to use 
a uniform 𝜏  for flow contrast imaging (37). From the view of 
𝜇𝑎
𝑑(𝜏, 𝒓) = 2𝜇𝑠′(𝒓)𝑘0
2𝛼𝐷𝐵(𝒓)𝜏, assigning uniform 𝜏 unifies the 𝜇𝑎
𝑑(𝜏, 𝒓) on the same time 
scale such that 𝜏 does not generate extra 𝜇𝑎
𝑑(𝜏, 𝒓) contrast. However, since the accuracy 
of the numerical model and computation of Jacobian matrix in NIRFAST software rely 
on optical properties (105) (here indicates 𝜇𝑎
𝑑(𝜏, 𝒓)), 𝜏 selection could influence ncDCT 
image reconstruction. To evaluate the 𝜏  selection influence, twenty τ values (1.0  
10−7 ≤  ≤ 6.4  10−5) from the entire range (generally from 1.0  10−7 to 1.0  10−3 
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s) were used to reconstruct DCT images. With each selected τ value, anomaly (tumor) 
was assigned 5-, 10- and 15-fold flow contrasts and the central depth was set at 7 and 10 
mm beneath the breast-shaped mesh surface. The reconstruction accuracies in tumor 
location and flow contrass were compared. 
 
4.3 Results 
4.3.1 ncDCT Recovered an Anomaly inside both Slab-shaped and Breast-shaped Tissue 
Volumes with Similar Accuracies  
Figure 4.3 illustrates 3-D (Figures 4.3a, 4.3b, 4.3e and 4.3f) and 2-D cross-section 
(Figures 4.3c, 4.3d, 4.3g and 4.3h) views of blood flow distributions in the slab-shaped 
(top panel) and breast-shaped (bottom panel) tissue volumes, respectively. Figures 4.3a, 
4.3e, 4.3c and 4.3g show the originally assigned/simulated anomaly inside tissue volumes 
and Figures 4.3b, 4.3f, 4.3d and 4.3h show the reconstructed results for comparisons. To 
clearly visualize the anomaly inside the tissue volume, 3-D background meshes were 
presented with 30% transparency of their original colors. The reconstructed anomalies 
were presented with FWHM thresholds in 3-D images (Figures 4.3b and 4.3f) and 
without thresholds in 2-D cross-section views (Figures 4.3d and 4.3h). Table 4.1 
summarizes the discrepancies between the assigned and reconstructed anomalies inside 
the slap-shaped and breast-shaped tissue volumes. These results indicate that the ncDCT 
system can recover the anomaly inside both slap-shaped and breast-shaped tissue 
volumes with similar accuracies. 
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Table 4.1: Computer simulation results in recovering an anomaly* inside slab-shaped 
and breast-shaped volume meshes. Table 1 
 
 
 
Anomaly 
central depth 
(mm) / % error 
Anomaly 
diameter (mm) 
/ % error 
Peak flow 
contrast (fold) 
/ % error 
Average 
flow contrast 
(fold) / % error 
Slab-shaped 6.4 / 8.6% 7.2 / 28% 12.8 / 28% 9.3 / 7% 
Breast-shaped 6.6 / 5.7% 7.5 / 25% 12.2 / 23% 8.1 / 19% 
 
*A spherical anomaly with a diameter of 10 mm and 10-fold flow contrast was placed at 
7 mm beneath the surface of background tissue volumes. 
 
 
 
 
Figure 4.3: Recovery of anomaly blood flow contrasts inside the slab-shaped and breast-
shaped volume meshes. A sphere anomaly with a diameter of 10 mm and 10-fold flow 
contrast was placed at 7 mm beneath the surface of background tissue volumes. (a) and 
(e) show the original assigned anomalies inside the volume meshes with sources and 
detectors aligned on the mesh surfaces; (b) and (f) show the reconstructed anomalies with 
FWHM thresholds; (c) and (g) show the 2-D cross-section views of original flow contrast 
distributions through the anomaly centers; (d) and (h) show the 2-D cross-section views 
of reconstructed flow contrast distributions. Figure 15 
 
 
 
(a)                               (b)                                (c)                               (d)
(e)                             (f)                                  (g)                               (h)
0.03
0.09
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4.3.2 Higher Reconstruction Accuracy Achieved when the Anomaly was within the 
Sensitive Region of Diffuse Light  
The reconstruction results with varied anomaly locations and flow contrasts are 
presented in Figure 4.4. The discrepancies (Figure 4.4b) between the reconstructed and 
assigned central locations of the anomaly were smaller than the mesh node distance (3 
mm) at all depths. The reconstructed anomaly locations were more accurate in the 
sensitive region of diffuse light (errors ≤ 0.5 mm at central depths ≤ 10 mm) compared to 
those in deeper depths.  
Reconstruction errors in peak and average BFI contrast of the anomaly at varied 
center location and assigned flow contrasts are displayed in Figure 4.4c. The largest 
reconstruction errors in peak and average flow contrasts ranged from 31.4% to -77.0% 
and -23.6% to -82.9% respectively through all varied depths and flow contrasts. Similarly, 
the reconstructed peak and average BFI contrasts were more accurate in the sensitive 
region of diffuse light (peak and average BFI underestimations ≤ 27.8% and 45.3% 
respectively at central depths ≤ 10 mm) compared to those in larger depths. 
Figures 4.4d and 4.4e demonstrate the linear relationships between the assigned and 
reconstructed peak and average BFI contrasts. The relative anomaly flow contrast 
changes were well reconstructed from the chosen central depths of 7 mm (peak BFI: 
linear regression slope = 1.03, R
2
 = 0.99, and p < 0.001; average BFI: linear regression 
slope = 1.02, R
2
 = 0.99, and p < 0.001), 10 mm (peak BFI: linear regression slope = 1.01, 
R
2
 = 0.97, and p < 0.01; average BFI: linear regression slope = 1.00, R
2
 = 0.97, and p < 
0.01), 13 mm (peak BFI: linear regression slope = 1.07, R
2
 = 0.98, and p < 0.01; average 
BFI: linear regression slope =1.07, R
2
 = 0.98, and p < 0.01), and 15 mm (peak BFI: linear 
56 
 
regression slope = 1.08, R
2
 = 0.98, and p < 0.01; average BFI: linear regression slope = 
1.08, R
2
 = 0.98, and p < 0.01). The relationships between the assigned and reconstructed 
relative anomaly flow contrast changes from other tested depths were similar (results not 
shown here). 
In total, these results indicate that relatively higher accuracies were achieved when 
the entire anomaly was within the sensitive depth of diffuse light. Also, even though the 
recovery of anomaly BFI contrasts was not as accurate as its location, the reconstructed 
anomaly BFI contrast changes were fairly accurate.  
 
 
Figure 4.4: Evaluation of reconstruction accuracy of ncDCT in the breast-shape volume 
mesh. (a) and (b) show the center location and deviation of the reconstructed anomaly at 
different depths; (c) shows the percentage deviations of anomaly peak and average BFI 
contrasts at different depths; (d) and (e) show the linear relationships between the 
assigned and reconstructed peak & average BFI contrasts at different depths. Figure 16 
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4.3.3 Noise Reduced Anomaly Recovery Accuracy  
Figure 4.5 shows the ncDCT image reconstruction results with simulated noise added 
to the forward problem. For comparisons, images reconstructed from clean data (no noise) 
and noisy data are plotted together. When the anomaly volume was within the sensitive 
region of diffuse light (anomaly central depth ≤ 10 mm), the largest discrepancy between 
the reconstructed and assigned central locations of the anomaly was 1.2 mm (Figure 
4.5b), 0.8 mm greater than that (0.4 mm) without noise. Similarly, the largest 
reconstruction errors in peak and average flow contrasts were 33.2% and 31.0% larger 
than those reconstructed without noise (Figures 4.5c and 4.5d). Apparently, adding noise 
reduced reconstruction accuracies in recovery of the anomaly. However, the major 
conclusions drawn in Chapter 4.3.2 are still valid. 
 
 
Figure 4.5: Noise influence on imaging accuracy of ncDCT. An anomaly was placed 
beneath the surface of the breast-shaped mesh with varied central depths from 7 mm to 
15 mm. (a) and (b) show the center location and deviation of the anomaly at different 
depths, reconstructed with or without noise. (c) and (d) show percentage deviations of 
anomaly peak and average BFI contrasts at different depths, reconstructed with or 
without noise. Figure 17 
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4.3.4 A Priori Knowledge of Anomaly Location and Volume Improved Flow Contrast 
Reconstruction  
Figure 4.6 demonstrates the improvements in the reconstruction of BFI contrasts 
using a priori knowledge of tumor location and volume in DCT image reconstruction. 
The top (Figures 4.6a to 4.6e) and bottom (Figures 4.6f to 4.6j) panels show the 
reconstructed results when the anomaly is at the central depth of 7 and 15 mm beneath 
the surface, respectively. In each panel, image results without/with a priori information 
and without/with noise are plotted respectively. The transect plots (Figures 4.6e and 4.6j) 
show the BFI distributions across the anomaly. The reconstruction accuracies in BFI 
contrasts were significantly improved when a priori knowledge of anomaly structural 
information was applied on data with and without noise. The peak/average BFI contrast 
errors were only 0.1%/4% (without noise) and 12.3%/12.3% (with noise) respectively 
when using a priori structural information for the anomaly located in the sensitivity 
region of diffuse light (i.e., at the central location of 7 mm, Figure 4.6e). The BFI 
contrast improvement at the deeper central depth of 15 mm was also remarkable (Figure 
4.6j).   
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Figure 4.6: Comparison of anomaly reconstructions without and with a priori structural 
information. The top (a to e) and bottom (f to j) panels show the reconstructed flow 
contrast distributions of an anomaly (assigned a 10-fold flow contrast) located at 7 and 15 
mm central depths, respectively. (a) and (f) show reconstructed results without the a 
priori structural knowledge of the anomaly; (b) and (g) show the reconstructed results 
with the a priori structural knowledge; (c) and (h) show the reconstructed results without 
the a priori structural knowledge and with noise. (d) and (i) show the reconstructed 
results with the a priori knowledge information and with noise. The flow contrast profiles 
crossing the yellow lines are shown in (e) and (j). Figure 18 
 
 
4.3.5 Optimization of τ Improved Imaging Accuracy 
Figure 4.7 shows the errors in the reconstructed anomaly locations and BFI contrasts 
with different τ selections. The discrepancies (Figure 4.7a) between the reconstructed 
and assigned central locations of the anomaly were smaller than the mesh node distance 
(3 mm) at all tested anomaly central depths and contrasts. The reconstructed anomaly 
locations were more accurate when τ was chosen in the range of  5.1  10−6  sec to 
1.91  10−5sec (between the two vertical lines in Figure 4.7a). Reconstruction errors in 
average BFI contrast with varied τ selections are displayed in Figure 4.7b. By choosing 
proper τ value, the error in reconstructed average flow contrast inside the anomaly can be 
reduced up to 27.6% (i.e., anomaly with 15-fold flow contrast located at 7 mm depth). 
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While smaller τ provided more accurate flow contrast reconstruction for anomaly located 
shallower, larger τ was more preferable for anomaly located deeper from mesh surface. In 
general, τ selected from certain range (5.1  10−6 ≤ 𝜏 ≤ 1.91  10−6 sec) between the 
two vertical lines shown in Figure 4.7b can provide more accurate results in flow 
contrast and location reconstructions.  
 
Figure 4.7: Evaluation of reconstruction accuracy of ncDCT with varied τ values based 
on meshes with 5-, 10- and 15-fold anomaly flow contrasts, and anomaly centroid located 
at 7 mm and 10 mm depths. (a) Shows deviation of the reconstructed anomaly center 
locations. Positive/negative values indicate deeper/shallower than original locations. (b) 
Shows reconstruction errors in average flow contrasts inside anomalies. Two pairs of 
black vertical lines in (a) and (b) are plotted at the same τ values, respectively, indicating 
the recommended τ intervals for image reconstruction. Figure 19 
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In this chapter, computer simulations were used to investigate the origins of flow 
reconstruction discrepancies. From the simulations, we observed similar reconstruction 
accuracies in blood flow contrasts and tumor central locations with slab-shaped and 
breast-shaped boundaries (see Figure 4.3 and Table 4.1), indicating the ability of ncDCT 
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simulations on breast-shaped geometry evaluated reconstruction accuracies when tumors 
had different flow contrasts and located at different depths. The results suggested that the 
reconstructed tumor location and flow contrasts were more accurate when the tumor 
volume was within the sensitive region of diffuse light (see Figure 4.4). Based on photon 
diffuse theory, the penetration depth of diffuse light is ~1/2 of the S-D separation (65, 67, 
101). The largest S-D separation of ncDCT was 30 mm, allowing for a penetration depth 
up to ~15 mm. As such, it was not surprising that the reconstruction errors increased as 
the tumor center located at a depth deeper than 10 mm.  
In contrast to the recovery of tumor location, the reconstruction of tumor blood flow 
contrasts was more complicated. The reconstructed peak BFIs were overestimated when 
the tumor located closer to the breast surface and underestimated when the tumor located 
out of the sensitive region of diffuse light (see Figure 4.4c). By contrast, the 
reconstructed average BFIs were consistently underestimated. These observations are 
similar to those in DOT for reconstruction of tumor absorption contrasts (106, 107). It is 
known from the DOT practice that imaging sensitivity is higher at the shallow region 
beneath tissue surface (108). Therefore, the reconstructed peak BFI from a single node 
close to the tissue surface tends to be overestimated. However, most of the reconstructed 
BFIs from the tumor node are prone to be underestimated due to the nature of inverse 
problem (109). Since the number of boundary data (S-D pairs) in ncDCT is much smaller 
than the unknowns to be solved (i.e., BFIs at all mesh nodes), the inverse problem is 
unstable (110), leading to the underestimation (106). In addition, according to the 
definition of 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏) = 𝜇𝑎(𝒓) + 𝜇𝑎
𝑑(𝒓, 𝜏), BFI reconstruction errors come from both 
“static” and “dynamic” absorption coefficients. Therefore, dynamic flow contrast errors 
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may be further enlarged by attributing all reconstruction errors of 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏) to dynamic 
𝜇𝑎
𝑑(𝒓, 𝜏) while ignoring static errors of 𝜇𝑎(𝒓). 
Similar to our previous findings (37), the relative changes of tumor flow contrasts can 
be accurately reconstructed in a large range of flow contrast variations (see Figures 4.4d 
and 4.4e). The observed linear relationships with a slope of close to “1” indicate the 
ability of ncDCT to capture tumor blood flow changes, which can be potentially used to 
longitudinally monitor tumor hemodynamic responses to interventions.  
As expected, adding noise reduced the reconstruction accuracies (see Figure 4.5). 
However, tumors can still be reconstructed clearly from the boundary data with noise (see 
Figure 4.5), indicating the feasibility of ncDCT for in vivo breast tumor detection. More 
importantly, adding a priori knowledge of the tumor volume and location improved 
significantly reconstruction accuracy (see Figure 4.6), which agrees with previous 
observations in DOT (94, 102, 104). 
Our previous publication has briefly discussed the selection of τ for image 
reconstruction (37). Five different τ values (4  10−7 ≤  ≤ 1.9  10−5 s) were selected 
for computer simulations, and the results showed little impact on the reconstructed flow 
contrast. Further investigation with a broad range of experimental configurations was 
conducted in this study. Simulations with extensive τ selections (1.0  10−7 ≤  ≤
6.4  10−5) have been performed to evaluate the influence on flow contrast and location 
reconstruction when the tumor was within the sensitive region of diffuse light. Different τ 
selections have smaller influence in the tumor location recovery compared with the flow 
contrast recovery. However, within the same range of τ selection (5.1  10−6 ≤  ≤
1.91  10−5 ) the reconstruction accuracies in both flow contrast and tumor central 
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location reconstructions are higher than with the other τ values. So we propose to select 
the range 5.1  10−6 ≤  ≤ 1.91  10−5 for future ncDCT image reconstruction.  
In conclusion, computer simulations based on different boundary geometries were 
performed to demonstrate the imaging capability of the novel ncDCT system on breast 
tumor detection. Results suggested that relatively high ncDCT image reconstruction 
accuracy can be achieved when the entire tumor was within the sensitive region of diffuse 
light. Image reconstruction with a priori knowledge of the tumor volume and location can 
significantly improve the accuracy in tumor blood flow contrast reconstruction. The 
optimized range of τ selection ( 5.1  10−6 ≤  ≤ 1.91  10−5 ) was provided to 
reconstruct ncDCT images with higher accuracies. Based on the computer simulation 
results, future development in instrumentation should increase the effective measurement 
pairs to reduce the underestimation nature of the inverse problem. Measurements from 
deep tissue are especially helpful to improve the image reconstruction accuracy. Depth 
correction algorithms should be integrated for ncDCT image reconstruction (i.e., increase 
the weights to information obtained from elements located deep inside mesh) such that 
tumor location recovery is more accurate even though the tumor was outside the sensitive 
region of diffusive light.    
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CHAPTER 5 NCDCT OF HUMAN BREAST TUMORS 
 
5.1 Introduction 
The autonomic growth and spread of malignant tumors are dependent on increased 
angiogenesis arising from the increased metabolic demand (111). Since functional 
alternations in tumors often appear earlier than detectable morphological changes, 
functional imaging of tumor hemodynamics and metabolism is a new strategy for early 
cancer diagnosis (112). Previous studies using different imaging modalities have found 
significant tumor-to-normal blood flow contrast in carcinomas, e.g., up to 12-fold 
contrast was found in post-menopausal women by PET (14, 113) and 3-fold contrast in 
flow velocity was also found by Doppler Ultrasound (114). Near-infrared (NIR) diffuse 
optical technologies provide a noninvasive and relatively inexpensive tool for functional 
imaging of tumor hemodynamics in deep microvasculature up to several centimeters (53-
55, 115). The most commonly used NIR diffuse optical spectroscopy/tomography 
(DOS/DOT) can quantify total hemoglobin concentration (THC) and blood oxygen 
saturation (StO2) in tumors (116, 117). DOS/DOT has been used over several decades to 
detect oxygenation alternations in breast tumors (32-36). For example, THC was found 
up to 2-fold higher in malignant lesions than nearby healthy tissues (117). More recently, 
a novel NIR diffuse correlation spectroscopy (DCS) technique has also been developed 
for direct measurement of blood flow index (BFI) in deep tissues (37). A few pilot studies 
of breast tumors using DCS have found increased blood flow inside the tumor in contrast 
to surrounding normal tissues (i.e., 2- to 10-fold flow contrasts) (53, 55). Real-time 
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monitoring of breast tumor blood flow response to neoadjuvant chemotherapy also 
demonstrated the potential of DCS for assessing cancer therapies (53, 56, 57). 
Our group has recently developed a novel noncontact DCT (ncDCT) system enabling 
3-D imaging of deep tissue blood flow distribution without contacting the tissue (37, 89, 
92). The imaging theory (Chapter 2), instrumentation of ncDCT system (Chapter 3) and 
validation work including computer simulations and phantom experiments were 
described (Chapters 3 and 4) in previous chapters. In this chapter, I report the first 3-D 
blood flow contrast imaging of human breast tumors using the noninvasive, noncontact 
diffuse correlation tomographic technique.  
 
5.2 Methods 
5.2.1 Subjects 
Twenty-eight female patients with breast tumors were recruited from University of 
Kentucky Comprehensive Breast Care Center with signed informed consent approved by 
the University of Kentucky Institution Review Board. According to our ncDCT system 
design and measurement protocol, patients with lesions located no deeper than 2 cm 
(central to breast surface, measured by ultrasound imaging) and from 9 o’clock to 3 
o’clock on the breast were recruited. There were no wound on patients’ breasts and all the 
patients had their scheduled biopsy procedures following the optical measurements. The 
biopsy results showed 7 patients had malignant tumors and 21 patients had benign lesions. 
The average age of the patients was 47.6 ± 16.3 years (see Table 5.1). 
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Figure 5.1: Schematic diagram (a) and ultrasound image (b) of breast lesion locations 
(118). Figure 20 
 
5.2.2 Experimental Protocol 
The patient was asked to lie in a supine position or on her side (with pillow support) 
according to the lesion location. The tumor lesion inside breast was determined by 
radiologists using ultrasound imaging prior to the optical measurement and marks were 
made on breast surface with mark pens. The tumor mass margin along the radio direction 
was also marked on the ultrasound images, which was used to compare with our 
reconstructed flow contrast images.    
9:00 3:00 9:00 3:00
≤ 2 cm
(a)                                                                                                             (b)
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Figure 5.2: Flow chart of experimental protocols. Figure 21 
 
 
The ncDCT probe was then aligned perpendicularly on top of the marked lesion 
region, with two sources evenly distributed on two sides of the lesion along the radio 
direction. Light intensities injected to breast tissue were adjusted to meet American 
National Standards Institute standards for laser safety usage (119). The ncDCT probe was 
then driven by a step motor to scan rotationally around the breast nipple over the region 
of breast tumor. The scanning procedures were similar to those described previously 
(Chapter 4.1.1). Briefly, multiple rotational scanning steps were taken to cover the tumor 
bearing region in the breast, with a 3-degree increment per step. For each patient, the 
number of scanning steps may vary depending on the tumor size and lesion location 
relative to the breast surface. Forty 𝑔2(𝒓, 𝜏) curves were collected from each source-
detector (S-D) pair for each patient. Two source pairs at the beginning and ending steps 
of scanning procedure and the rotation center were visually marked on the breast surface 
as references for the alignment of sources and detectors on the surface mesh. The surface 
3-D Camera
Scanning -
Reference Plane
(5min)
Tissue µa µs’
Measurement 
with Imagent
(5 min)
3-D Camera
Scanning - Breast
(5 min)
ncDCT Scanning
(25 min)
Ultrasound 
Imaging
(5 min)
Patient Measurement Takes ~ 40 min
68 
 
geometry of the breast with the source and rotation center marks was then recorded by a 
commercial 3-D camera for image reconstruction. Following the ncDCT measurement, 
the Imagent was used to measure 𝜇𝑠
′  and 𝜇𝑎 of the breast tissue at three different locations 
(Chapter 3.3.3) (71). The averaged  𝜇𝑠
′  and 𝜇𝑎 over the multiple sites were used as initial 
inputs for flow image reconstruction. After the patient leaves the measurement bed, 
another photo of the ncDCT probe and the reference plane was taken for the alignment of 
the scanned source and detector coordinates onto the breast-shaped mesh. The total 
measurement time on patient is around 40 minutes (Figure 5.2). 
 
5.2.3 Image Reconstruction 
The solid breast mesh of the patient was created in the same way as that of plastic 
mannequin breast (Chapter 4.1.1). The node distance was 3 mm in the ROI and 6 mm in 
the surrounding region. Boundary BFIs on the breast mesh surface were then extracted by 
fitting the measured 𝑔2(𝒓, 𝜏) curves from effective S-D pairs. These boundary BFI data 
were then calibrated to the BFIs collected at the first scanning step where the tissue 
underneath the probe was outside the tumor region and thus assumed to be homogeneous 
and healthy. The calibrated boundary data were finally used for DCT image 
reconstruction.  
Noise Influence Evaluation. Apart from the noises mentioned in computer 
simulations originated from electronics and optics, there were other noises in the breast 
tissue measurements. Those additional noises include physiological noises such as 
respiration and heart beating, motion artifacts such as patients’ body gesture changes and 
tumor heterogeneity caused noise during light propagation in tissues. In order to evaluate 
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the noise influence, the coefficients of variation (Cv) in extracted boundary BFIs from 
breast tissues and liquid phantoms were compared: 
𝐶𝑣 =
𝑠𝑡𝑑 (𝐵𝐹𝐼)
𝑚𝑒𝑎𝑛 (𝐵𝐹𝐼)
                                                     (5.1) 
For patient measurements, the Cv of boundary BFIs from each scanning step were 
calculated according to Equation 5.1. According to the protocol for breast tissue 
measurements, there were 40 optical measurements per step from each source-detector 
pair. For liquid phantom measurements, same measurement procedures were performed 
following the in vivo measurements, with same optical properties and detected light 
intensities. 
The boundary BFI data from one patient with invasive ductal carcinoma (Patient No. 
19) was analyzed as an example. This patient kept her body position well during the 
scanning of ncDCT. Figure 5.3a shows the mean values and standard deviations of the 
normalized boundary BFIs/flow indices obtained at one single S-D pair (2 cm S-D 
separation) in the breast tissue (over tumor region) and phantom solution. Figure 5.3b 
plots the Cv values at all steps according to Figure 5.3a. The averaged Cv values for the 
breast tissue and phantom measurements were 0.105 ± 0.017 and 0.089 ± 0.004, 
respectively. Significant differences were found between the two groups of Cv values (p 
= 0.005). Large variations observed from the patient were likely due to the physiological 
noises in in vivo measurements.     
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Figure 5.3: The effect of additional noises on in vivo breast tissue measurement from one 
patient analysis. (a) Normalized boundary BFI measured on breast and phantom solution 
by recording one source-detector measurement pair through 15 scanning steps. (b) The 
coefficients of variation derived from (a). Figure 22 
 
 
The Cv values from other patients’ measurement data may vary due to the stability of 
patients’ body positions during measurements. Therefore, the data with obvious motion 
artifacts (with large Cv values) were excluded from the image reconstruction.  
 
5.3 Results 
5.3.1 Representative Individual Results 
Representative 3-D reconstructed images from two patients with malignant cancers 
and two subjects with benign lesions are shown in Figures 5.4-5.7. 
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Figure 23 
Figure 5.4: Clinical example of ncDCT imaging result from case 1. (a) Patient No. 16 
ultrasound image taken from radio direction shows a 10.2 × 6.65 mm
2
 oval mass (inside 
the yellow dashed circle) with circumscribed margins parallel to the skin. The mass 
center is located at 19.2 mm beneath the skin surface. A core biopsy revealed a ductal 
papilloma with low-grade ductal adenocarcinoma in situ. (b) Shows the reconstructed 3-
D tumor blood flow contrasts with FWHM threshold (pink mass). The red and yellow 
dots indicate scanned source and detector locations. (c) Shows the cross-section view, 
which is displayed in (b), through the reconstructed tumor center. The reconstructed 
tumor center is 10.8 mm deep. S1 and S3 are one pair of projected source locations at one 
scanning step. (a) was taken with ultrasound transducer aligned from S1 to S2. 
 
Case 1 (Patient No.16): Ductal Papilloma with Low-grade Ductal Adenocarcinoma in 
situ (malignant) 
The first case (Patient No. 16) was a 59-year-old female who had ductal papilloma 
and low-grade adenocarcinoma in situ. According to the ultrasound imaging (Figure 
5.4a), the lesion with the dimension of 10.2 × 6.65 mm
2
 was located at 19.2 mm beneath 
the skin surface. The dimension of the reconstructed tumor by ncDCT with the full width 
half-maximum (FWHM) threshold was approximately 15.1 × 5.8 mm
2
 (Figure 5.4c), 
which matched ultrasound image. However, the reconstructed tumor central location was 
10.8 mm beneath the breast surface, which differed from the ultrasound image result 
(19.2 mm). The 2-D cross-section view shown in Figure 5.4c was cut along the radio 
direction of scanning and through the tumor center and breast nipple (see extracted cross-
8.3
s1 s2
s1
s2
s1
s2
(a)                                  (b)                                     (c)       
-1.6
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section in Figure 5.4b). The peak and average tumor blood flow contrasts were 8.3-fold 
and 5.9-fold, respectively. Note that measurement noise caused some artifacts with 
𝜇𝑎
𝑡𝑜𝑡𝑎𝑙(𝒓, 𝜏)  lower than static 𝜇𝑎(𝑟)  in the region bordering the reconstructed tumor, 
leading to some negative flow values.  
 
Figure 5.5: Clinical example of ncDCT imaging result from case 2. (a) Patient No. 26 
ultrasound image taken from radio direction shows a 8.5 × 3.5 mm
2
 mass (inside the 
yellow dashed circle), located at 13.3 mm beneath the skin surface. A core biopsy 
revealed atypical ductal hyperplasia and low-grade carcinoma in situ. (b) Shows the 
reconstructed 3-D tumor blood flow contrasts with FWHM threshold (big pink mass is 
the reconstructed tumor, the other two masses are artifacts). The red dots indicate 
scanned source locations. (c) Shows the cross-section view through the reconstructed 
tumor center. The reconstructed tumor center is 12.4 mm deep. Figure 24 
 
 
Case 2 (Patient No. 26): Atypical Ductal Hyperplasia and Low Grade Carcinoma 
in situ (maligant) 
The second case (Patient No. 26) was a 49-year-old female who had an atypical 
ductal hyperplasia and low-grade carcinoma in situ. Ultrasound images (Figure 5.5a) 
show that the lesion centroid was located at 13.3 mm beneath the skin surface with the 
dimension of 8.5 × 3.5 mm
2
. Our ncDCT imaging results show a clear large tumor lesion 
with two small suspicious artificial anomalies (Figure 5.5b). The dimension of the 
reconstructed large tumor was approximately 12.3 × 5.1 mm
2
 (Figure 5.5c) and its 
12.4
s1 s2
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s2
(a)                                  (b)                                     (c)       
16.8
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s2
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central depth was 12.4 mm beneath the breast surface, which fairly matched the 
ultrasound imaging result. The peak and average blood flow contrasts were 14.0-fold and 
10.6-fold, respectively. Artifacts with negative flow values were also observed in the 
region bordering the reconstructed tumor. 
 
 
Figure 5.6: Clinical example of ncDCT imaging result from case 3. (a) Patient No. 22 
ultrasound image taken from radio direction shows a 8.3 × 7.6 mm
2
 mass (inside the 
yellow dashed circle), located at 10.0 mm beneath the skin surface. A core biopsy 
revealed a lymphocytic lymphoma. (b) Shows the reconstructed 3-D tumor blood flow 
contrasts with FWHM threshold (pink mass). The backgrounds are presented with 30% 
transparency of the original color clarity. (c) Shows the cross-section view through the 
reconstructed tumor center. The reconstructed tumor center is 8.3 mm deep. Figure 25 
 
 
Case 3 (Patient No. 22): Lymphocytic Lymphoma (benign) 
The third case (Patient No. 22) was a 61-year-old female who had lymphocytic 
lymphoma. According to the ultrasound imaging (Figure 5.6a), the lesion with the 
dimension of 8.3 × 7.6 mm
2
 was located at 10.0 mm beneath the skin surface. The 
dimension of the reconstructed tumor with FWHM threshold was approximately 4.5 × 
10.5 mm
2
 (Figure 5.6b) and its central depth was 8.3 mm beneath the breast surface 
(a)                                              (b)                                       (c) 
8.3
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(Figure 5.6c), which matched ultrasound imaging result. The peak and average tumor 
blood flow contrasts were 6.5- and 4.9-fold, respectively.  
 
 
Figure 5.7: Clinical example of ncDCT imaging result from case 4. (a) Patient No. 20 
ultrasound image taken from radio direction shows a 10.4 × 2 mm
2
 mass (inside the 
yellow dashed circle), located at 5.8 mm beneath the skin surface. A core biopsy revealed 
a fibroadenoma, no atypical features identified. (b) Shows the reconstructed 3-D tumor 
blood flow contrasts with FWHM threshold (pink mass). (c) Shows the cross-section 
view through the reconstructed tumor center. The reconstructed tumor center is 6.0 mm 
deep. Figure 26 
 
Case 4 (Patient No. 20): Fibroadenoma (benign) 
The fourth case (Patient No. 20) was a 24-year-old female who had fibroadenoma 
without atypical features. According to the ultrasound imaging (Figure 5.7a), the lesion 
with the dimension of 10.4 × 2.0 mm
2
 was located at 5.8 mm beneath the skin surface. 
The dimension of the reconstructed tumor was approximately 7.1 × 2.6 mm
2
 (Figure 
5.7b) and its central depth was 6.0 mm beneath the breast surface (Figure 5.6c), which 
matched ultrasound image. The peak and average tumor blood flow contrasts were 13.3-
fold and 8.6-fold, respectively. Artifacts with negative flow values were observed in the 
region bordering the reconstructed tumor. 
6.0
(a)                                          (b)                                        (c) 
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5.3.2 Group Results 
Table 5.1 summarized group imaging results from in vivo breast tumor measurements. 
Higher tumor-to-normal blood flow contrasts were observed in the majority of patients 
measured by our ncDCT system (18 out of 28). The peak/average tumor-to-normal blood 
flow contrasts, the reconstructed tumor location and dimension were quantified, using the 
same methods described in Chapter 4.  
Reconstructed tumor depths and dimensions matched ultrasound images well when 
the tumors were within the sensitive region of diffuse light (depth of ~ 1.5 cm). For the 
benign group with observed blood flow contrasts (n = 14), the averaged blood flow 
contrasts in the reconstructed tumor regions were 18.0 ± 7.0 (peak flow) and 12.6 ± 4.7 
(mean flow) folds, while the corresponding blood flow contrasts in the malignant group 
(n = 4) were 16.0 ± 6.1 (peak flow) and 10.6 ± 3.3 folds (mean flow). No significant 
difference was found in blood flow contrasts between the two groups. 
Tumor-to-normal blood flow contrasts were not observed in some patients’ 
reconstruction results. Among those cases, three patients’ data was contaminated by 
motion artifacts, one patients’ lesion region was not able to be covered completely by 
ncDCT probe (patient No. 5, lesion was 55 mm long located beneath the nipple), and 
three patients’ data collection procedures were normal. The lesion types for three patients 
with smooth measurements were non-proliferative fibrocystic changes (patient No. 3, 8.7 
mm dimension, 12.7 mm central to surface depth), duct ectasia (patient No. 6, 3.5 mm 
dimension, 11.6 mm depth) and breast tissue with no significant pathologic abnormality 
(patient No. 28, 9.9 mm × 2.4 mm dimension, 8.1 mm depth). In addition, three patients’ 
reconstruction results were excluded from image reconstruction since the measurement 
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procedures were incorrect (n = 2) and the measurement was stopped due to the instrument 
malfunction (n = 1).  
 
Table 5.1:  Group imaging results from in vivo breast tumor measurements.Table 2 
 
No. Race Age 
Tumor biopsy results ncDCT imaging 
US 
imaging 
depth 
 / mm 
Type Description 
Peak 
flow 
/ fold 
Mean 
flow 
/ fold 
Depth 
/ mm 
1 W 44 B fibroadenoma Excluded  (reason A)  NA 
2 W 46 B intraductal papilloma Excluded (Reason A) 20.3 
3 W 36 B 
non-proliferative fibrocystic 
changes 
No contrast observed 
(Reason C) 
12.7 
4 W 60 B complex fibroadenoma Excluded (Reason B)  12.0 
6 W 57 B duct ectasia 
No contrast observed 
(Reason C) 
11.6 
9 W 22 B 
fibroadenoma with usual 
ductal hyperplasia 
20.2 14.3 9.7 12.8 
10 B 30 B fibroadenoma 19.1 13.2 9.1 14.1 
11 B 71 B intraductal papilloma 11.8 8.5 9.2 11.5 
12 B 27 B fibroadenoma 17.6 13.6 13.0 10.3 
13 W 55 B fat necrosis 18.3 13.6 6.2 5.5 
15 W 29 B cellular fibroadenoma  15.7 10.3 10.2 9.5 
17 W 63 B 
intraductal papillomas with 
atypical ductal hyperplasia 
25.1 17.2 11.2 27.0 
18 B 41 B 
nodular adenosis with 
associated microcalcification 
18.9 12.6 13.8 15.0 
20 B 24 B fibroadenoma 13.3 8.6 6.0 5.8 
21 W 47 B 
proliferative fibrocystic 
features 
17.3 12.1 12.3 19.0 
22 W 61 B lymphocytic lymphoma 6.5 4.9 8.3 10.0 
23 W 62 B stromal fibrosis 
 No contrast observed 
(reason B) 
22.2 
24 H 20 B 
fibroadenoma with myxoid 
stroma 
26.7 17.9 5.9 12.2 
25 W 44 B 
cellular fibroadenoma, cannot 
exclude benign phyllodes 
8.2 6.6 10.6 14.8 
27 
W 40 B 
proliferative fibrocystic 
change with prominent cyst 
formation and extensive 
papillary apocrine metaplasia 
32.8 22.4 9.7 11.5 
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Table 5.1 (continued) 
28 B 64 B 
breast tissue with no 
significant pathologic 
abnormality 
No contrast observed 
(Reason C) 
8.1 
Benign 
tumor 
summary  
Total number of reconstructed tumors / measured: 14 / 21 
Peak flow contrast: 18.0 ± 7.1fold 
Mean flow contrast: 12.6 ± 4.7 fold 
5 H 32 M 
infiltrating moderately to 
poorly differentiated ductal 
adenocarcinoma 
No contrast observed 
(Reason A) 
20.0  
7 W 71 M 
invasive moderately 
differentiated ductal 
carcinoma 
No contrast observed 
(Reason B) 
10.0 
8 W 63 M 
intracystic/encysted papillary 
carcinoma in situ 
No contrast observed 
(Reason B) 
10.0 
14 W 73 M 
invasive poorly differentiated 
ductal adenocarcinoma 
21.5 12.4 7.6 19.4 
16 B 59 M 
ductal papilloma with low-
grade ductal adenocarcinoma 
in situ 
8.3 5.9 10.8 19.2 
19 W 54 M invasive ductual carcinoma 20.1 13.4 15.9 20.0 
26 W 49 M 
atypical ductal hyperplasia 
and low grade carcinoma in 
situ 
14.0 10.6 12.4 13.3 
Malignant 
tumor 
summary 
Total number of reconstructed tumors / measured: 4 / 7 
Peak flow contrast: 16.0 ± 6.1fold 
Mean flow contrast: 10.6 ± 3.3 fold 
W: White; H: Hispanic; B: Black 
M: Malignant; B: Benign 
US: Ultrasound 
Reasons for no tumor flow contrasts : A – lesion region could not be covered completely 
by ncDCT probe; B – data was contaminated by motion artifacts (i.e., body gesture 
changed and coughed); C – data collection was normal, however, no flow contrast was 
observed. 
Excluded reasons: A – measurement procedure was invalid (i.e., source and detector 
scanning coordinates couldn’t be correctly aligned on the mesh); B – measurement was 
stopped due to the instrument malfunction.  
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5.4 Discussion and Conclusions 
Since increased angiogenesis in breast tumor is commonly associated with blood flow 
increase, imaging of blood flow distribution in breast tissue is of great importance for 
tumor detection (111). Previous phantom experiment and computer simulations 
(Chapters 3 and 4) have demonstrated the feasibility of applying ncDCT system for 
breast tumor flow contrast imaging. The remaining challenge lies in handling potential 
problems arising from the in vivo measurements.  
In this chapter, preliminary study of human breast tumor imaging with ncDCT system 
was performed. Higher blood flow contrasts in the tumor regions compared to the 
surrounding tissues were observed in most of measured breast tumors. In reconstructed 
ncDCT images with higher blood flow contrasts, the tumor positions on the x-y plane 
agreed well with ultrasound imaging results (see examples in Figures 5.4b-5.7b). The 
reconstructed tumor central depth matched the ultrasound image when tumors were 
located within the sensitive depth of diffuse light (see examples in Figures 5.5c-5.7c). 
For some patients, the reconstructed tumor central depths were shallower than ultrasound 
imaging result (see example in Figures 5.4c). These were likely due to the fact that 
tumors were deeper than the depth where diffuse light cannot reach with our current 
ncDCT system.  
It has been demonstrated by computer simulations (Chapter 4.2.4) that a prior 
knowledge of tumor location and volume can improve image reconstruction accuracy. 
However, due to the difficulty of co-registering the 2-D ultrasound image and 3-D 
ncDCT image, it was not possible in this study to apply the a priori structural knowledge 
of tumor for improving the accuracy of image reconstruction in patients. Future study 
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may utilize 3-D anatomical imaging modalities such as MRI or CT to obtain accurate 
priori structural information of the tumor.  
The averaged mean values of tumor-to-normal blood flow contrasts for two groups of 
breast tumors were 10.6 ± 3.3 -fold (malignant) and 12.6 ± 4.7 -fold (benign). The results 
were comparable to previously reported flow contrasts of 2- to 10-fold in breast tumors 
detected by DCS (53, 55). It should be noted that the tumor flow contrasts quantified 
previously by DCS may be underestimated due to the partial volume effect by the healthy 
tissues surrounding the tumor. In addition, the potential crosstalk between 𝜇𝑎, 𝜇𝑠
′  and BFI 
may also result in over- or under-estimation of blood flow contrasts in both DCS and 
ncDCT (67, 83). According to the definition of 𝜇𝑎
𝑡𝑜𝑡𝑎𝑙, 𝜇𝑎, 𝜇𝑠
′  and 𝛼𝐷𝐵, variations cannot 
be completely separated unless they are independently measured. As previous computer 
simulations suggested ~250% variation in 𝜇𝑠
′   distribution may cause ~297%  variation in 
BFI reconstruction, while 200 to 300% variations in 𝜇𝑎  may cause 11.5%  to 26% 
variations in BFI reconstruction (Chapter 3.3.2). So when assuming homogeneous 
optical properties  over the entire breast, the realistic heterogeneous optical properties 
(mainly due to 𝜇𝑠
′)  across the tumor can generate errors in tumor BFI contrasts. To 
overcome this limitation, a separate instrument enabling 3-D imaging of 𝜇𝑎 and 𝜇𝑠
′  
distributions in the breast is needed (e.g., a frequency-domain or time-resolved DOT (32, 
120-122)). 
We didn’t find difference in the reconstructed blood flow contrasts between the 
benign and malignant breast tumors. Since the number of reconstructed images from two 
groups of patients was small (n = 14 for benign and n = 4 for carcinoma), the extracted 
blood flow contrasts may not be generalizable to two groups of patient populations. 
80 
 
Furthermore, some studies also showed similar densities of microvasculature between the 
low grade breast carcinomas and benign lesions (123), which might result in the overlap 
of blood flow contrasts between malignant tumors and benign lesions. In addition, 
measurement and reconstruction errors as mentioned earlier may cause difficulty in 
distinguishing different tumor types. For example, the crosstalk between the optical 
properties (mainly due to 𝜇𝑠
′ ) and BFI may induce errors in the reconstructed tumor-to-
normal blood flow contrasts. Tumors located at varying depths may lead to certain 
amount of over- or under-estimations in BFI reconstruction. 
In the future study, we should optimize the imaging system and increase patient 
number to investigate the possibility of using ncDCT for characterization/classification of 
breast tumors. Overall, the current study demonstrated the potential of ncDCT system to 
be used for imaging blood flow distributions in soft and vulnerable tissues without 
distorting tissue hemodynamics. 
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CHAPTER 6 OPTICAL FIBER MODE OPTIMIZATION FOR BETTER 
SIGNAL-TO-NOISE RATIO (SNR) 
 
6.1 Introduction 
As described in Chapter 2, NIR light has been recently employed to noninvasively 
measure rBF in deep tissues, which is referred to as NIR DCS (38, 41, 54, 58, 65, 75-77, 
124) or diffusing wave spectroscopy (DWS)  (82, 125, 126). Further development of 
DCS technology includes ncDCT for 3-D blood flow imaging (Chapters 3-5) and a dual-
wavelength DCS flow-oximeter (41, 46, 67, 78, 124, 127), which can simultaneously 
measure rBF and oxygenation variations. High SNR is crucial when applying DCS 
technologies in study of human tissues where the detected signals are usually very weak 
(41, 46, 54, 67, 75-78, 92, 127, 128). In this chapter, I report a study exploring the use of 
different types of detector fibers to experimentally compare/improve the SNRs of DCS 
flow-oximeter measurements (129).  
When using DCS to detect tissue blood flow, a pair of source and detector fibers is 
usually placed along the tissue surface. Previous studies have used either single-mode (40, 
41, 53, 60, 75, 76, 92, 124, 127, 130) or few-mode (131-134) fibers separately for DCS 
flow detections. A single-mode fiber is an optical waveguide whose very small core 
radius is comparable with the wavelength of the transported light (131, 135). Light 
intensity detected by the single-mode fiber, however, is low due to the fact that only the 
fundamental mode of light can be transported. By contrast, few-mode fibers allow a few 
higher order modes of light to be guided through the fiber along with the fundamental 
mode. Enlarging the fiber diameter and numerical aperture (NA) with few-mode fibers to 
cover multiple speckles increases the detected signal intensity, thus improving SNR. 
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Conversely, the multiple speckles detected by the few-mode fibers are uncorrelated and 
decrease the coherence factor (β) in a proportional fashion (131-134). As a result, the 
autocorrelation function curve becomes flatter which may reduce the sensitivity of DCS 
flow measurements (60, 136). The detected light intensity can be further increased using 
multi-mode fibers with a large core diameter (e.g., 1 mm), although the autocorrelation 
function may not be detectable due to very low value of β (i.e., the autocorrelation 
function curve becomes a straight line) (135, 137).  
Dual-wavelength DCS flow-oximeter was developed by including a second laser to 
the DCS device, which enables the extraction of multiple hemodynamic variables 
including rBF and changes in oxy-hemoglobin concentration (∆[HbO2]) and deoxy-
hemoglobin concentration (∆[Hb]). As mentioned earlier, few-mode and multi-mode 
fibers collect more photons than single-mode fibers which leads to the following 
hypothesis. Increased light intensities measured at two wavelengths by few-mode or 
multi-mode fibers should improve the SNRs in measurements of light intensity as well as 
tissue blood oxygenation.  
In this chapter, three fibers with different modes (i.e., single-mode, few-mode or 
multi-mode) were examined in tissue-like liquid phantoms with varied optical properties 
and in human forearm muscles during arterial cuff occlusion. The SNRs of the measured 
variables were calculated and compared to aid in the selection of fiber(s) for the 
improvement of DCS flow-oximeter measurements. 
The work reported in this chapter has been published (129) and reprint permission for 
this dissertation has been granted by the publisher. 
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6.2 Methods and Materials 
6.2.1 DCS Flow-oximeter 
Flow Measurements. DCS flow indices were quantified by a dual-wavelength DCS 
flow-oximeter with two CW coherent laser sources at 785 and 853 nm (100 mw, 
Crystalaser, Inc., NV) (46). The coherence length for both lasers was longer than 5 
meters. The two DCS sources emitted NIR light alternately into the tissue via two multi-
mode optical fibers with a core diameter of 200 µm (WF200/220/245, Ceramoptec, MA) 
bundled at the same location on the phantom/tissue surface. Three detector fibers, 
including a single-mode fiber with a core diameter of 4.3 µm (SM600, Fibercore, CA), a 
6-mode fiber with a core diameter of 4.5 µm (SM980, Fibercore, CA) and a multi-mode 
fiber with a core diameter of 1 mm, were confined by a foam pad at an equal distance of 
2.5 cm from the two source fiber bundle (Figure 6.1). These detector fibers were 
connected respectively to three single-photon-counting APDs (PerkinElmer Inc., Canada) 
inside the DCS device. The outputs of APDs were sent to a 4-channel autocorrelator 
board yielding normalized light intensity temporal autocorrelation functions 𝑔2(𝒓, 𝜏). As 
described in DCS theory section (Chapter 2.3), by fitting the analytical expression of 
𝑔2(𝒓, 𝜏) with the 𝑔2(𝒓, 𝜏) from measurement, the blood flow index αDB and coherence 
factor β are extracted simultaneously. 
Optical Property Measurements. DCS for flow measurement needs only one 
wavelength of light source. Adding a second laser to the DCS device allows for 
simultaneous measurements of tissue optical properties. Photons emitted by lasers are 
scattered and/or absorbed when they travel through the tissue from the source to detector, 
leading to light intensity reductions in detected wavelengths. Similar to CW NIRS, the 
84 
 
relative change in the tissue absorption coefficient (∆μa) can be derived from the light 
intensity changes measured at the two wavelengths (138). Variations of ∆[HbO2] and 
∆[Hb] relative to their baseline values (determined before physiological changes) can be 
determined from the measured ∆μa at two wavelengths, using the modified Beer-Lambert 
Law (73), 
∆[HbO2] =
𝜀𝐻𝑏(𝜆1)∆𝜇𝑎(𝜆2)−𝜀𝐻𝑏(𝜆2)∆𝜇𝑎(𝜆1)
𝜀𝐻𝑏(𝜆1)𝜀𝐻𝑏𝑂2(𝜆2)−𝜀𝐻𝑏𝑂2(𝜆1)𝜀𝐻𝑏(𝜆2)
  , 
∆[Hb] =
𝜀𝐻𝑏𝑂2(𝜆2)∆𝜇𝑎(𝜆1)−𝜀𝐻𝑏𝑂2(𝜆1)∆𝜇𝑎(𝜆2)
𝜀𝐻𝑏(𝜆1)𝜀𝐻𝑏𝑂2(𝜆2)−𝜀𝐻𝑏𝑂2(𝜆1)𝜀𝐻𝑏(𝜆2)
 .                           (6.1) 
Here ∆𝜇𝑎(𝜆) =   (𝐼𝜆𝐵 𝐼𝜆𝑇⁄ ) /(𝑑DP λ) , 𝐻𝑏𝑂2(𝜆)  and 𝐻𝑏(𝜆)  are the extinction 
coefficients of oxyhemoglobin and deoxyhemoglobin. 𝐼𝜆𝐵 and 𝐼𝜆𝑇 are the measured light 
intensities at the baseline and time T, respectively. The differential path length factor 
(DP λ) denotes the ratio of the mean photon path length to the distance (𝑑) between the 
source and detector pair. 
 
6.2.2 Optical Fiber Modes 
For an optical fiber the number of guided modes depends on the core radius (a), 
relative refractive-index difference, and operating wavelength (λ). The relation between 
the properties of a given dielectric optical waveguide (fiber) and guided waves (number 
of modes) can be described by introducing a normalized frequency V (135):  
𝑉 =
2𝜋𝑎
𝜆
√𝑛1
2−𝑛2
2                                                           (6.2) 
Here n1 and n2 are the refractive indices of fiber core and cladding, respectively. The 
square root of (n1
2
 - n2
2
) is defined as numerical aperture NA. When V is smaller than the 
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critical cutoff frequency VC (e.g., 2.405 for a step-index fiber whose refractive index is 
constant within the fiber core), only the fundamental mode LP01 can be guided through 
the fiber. Notice that a single-mode fiber can transmit two independent orthogonally 
polarized waves; the fiber is actually “bimodal” (135). The operating wavelength 
corresponding to VC is called the cutoff wavelength (λC). When the value of V is larger 
than VC, the fiber can guide a few higher-order modes along with the fundamental mode; 
it becomes a few-mode fiber. The propagating vector modes, i.e., the transverse electric 
mode (TE), transverse magnetic mode (TM), or hybrid mode, can be determined by the 
following three steps: (1) calculating the V value based on the fiber property using 
Equation 6.2; (2) using the V value to obtain transported linear polarized (LP) modes 
corresponding from literature values (139) where the LP modes are the eigen-modes of 
guided conventional modes (i.e., TE, TM, hybrid mode) and each of them has designation 
of conventional modes (wave modes) (137); (3) determining the guided wave modes 
according to the compositions of different LP modes.  
We used three detector fibers for photon collection in our experiments. According to 
the method described above, the single-mode fiber (SM600) has a λC of ~600 nm, NA 
between 0.1 and 0.14, and fiber core diameter of ~4.3 μm which guides only two 
orthogonal polarization modes of light at the two operating wavelengths of 785 and 853 
nm (135). The few-mode fiber (SM980) has a λC of ~970 nm, NA between 0.17 and 0.19, 
and fiber core diameter of ~4.5 μm which guides six modes of light operating at both 785 
and 853 nm wavelengths. In Chapter 6.3.1 we experimentally checked and confirmed 
these calculated numbers of guided modes using measured values of 1/β. The third fiber 
used is a regular multi-mode fiber with a diameter of 1 mm. 
86 
 
6.2.3 Phantom Experiments 
Distilled water, India ink and Intralipid were utilized in constructing liquid phantoms 
which provided a homogeneous tissue model (see details in Chapter 3.4.1) (41, 67, 92).  
An optical probe shown in Figure 6.1 was placed on the surface of the liquid phantom 
solution contained inside a glass aquarium. A custom-made probe holder attached to a lab 
stand held the probe at the center of solution to simulate a semi-infinite geometry. Room 
light was turned off during experiments. In order to test the SNR at different levels of 
light intensity, a titration protocol of gradually varying µa was applied. The optical 
property of liquid phantom was set initially at µa = 0.05 cm
-1 
and µs’ = 8 cm
-1
 at 853 nm. 
The corresponding µa and µs’ for the second wavelength (785 nm) at each titration step 
were calculated according to the volumes of water, India ink and Intralipid in the 
phantom solution (67). The µa (853 nm) was then gradually increased up to 0.15 cm
-1 
at a 
step size of 0.025 cm
-1 
by adding ink to the liquid phantom while µs’ was kept constant 
(without changing the concentration of Intralipid). Optical measurements were taken by 
the DCS flow-oximeter for 10 minutes at each titration step and 260 𝑔2(𝒓, 𝜏) curves were 
collected for each wavelength. The measurement duration for each autocorrelation 
function at each wavelength was 1 second. Only 150 data points measured at each 
wavelength and each step were used for data analysis, as the noisy data collected during 
the periods of adding, stirring and dissolving ink were excluded. At the final step of the 
titration (µa = 0.15 cm
-1
), the light intensity collected by the single-mode fiber (SM600) 
reached a minimal value of ~10 kilo counts per second (kcps) that could barely be 
detected by DCS. 
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Figure 6.1: A fiber-optic probe consisting of two source fibers (S1 = 785 nm and S2 = 
853 nm) and three detector fibers (D1 to D3). Multi-mode fiber (1mm) locates in D1, 
single-mode fiber (SM600) locates in D2, and few-mode fiber (SM980) locates in D3. The 
separations between the sources and detector fibers are equal (i.e., SD1 = SD2 = SD3 = 2.5 
cm). The separations between detector fibers are D1D2 = 4.6 cm, D1D3 = 4.3 cm and D2D3 
= 0.8 cm, respectively. Figure 27 
 
 
For flow data analysis theoretical µa and µs’ from the phantom at each titration step 
were used as inputs when fitting flow index DB (67). Relative changes in DB were 
calculated by normalizing/dividing the time-course data to the mean values of the first 
titration data. For the analysis of phantom absorption coefficient, µa (λ) at the first 
titration step was assigned to be the theoretical value of the phantom (e.g., µa (853 nm) = 
0.05 cm
-1
) and µa (λ) values at other titration steps were then calculated by adding the 
corresponding ∆µa (λ) values measured by the DCS flow-oximeter. Standard deviations 
of the measured variables were calculated and displayed as error bars along with the 
mean values. 
 
6.2.4 In vivo Tissue Measurements 
The single-mode, few-mode and multi-mode fibers were further used to investigate 
the SNRs in DCS flow-oximeter measurements on human tissues. The in vivo 
experiments were approved by the University of Kentucky Institutional Review Board. 
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Seven healthy subjects signed consent forms and participated in this study. Each subject 
was asked to lay supine on a bed and extend his/her forearm. Prior to the DCS flow-
oximeter measurement the commercial tissue-oximeter Imagent with a hand-held probe 
was used to obtain absolute baseline values of µa, µs’, [Hb] and [HbO2] in the 
participant's forearm flexor carpi radialis muscle (71). The hand-held probe was removed 
and the fiber-optic probe developed for this study (Figure 6.1) was taped on the same 
location in forearm muscle to continuously monitor rBF, ∆[Hb] and ∆[HbO2] during 5-
minute arterial cuff occlusion. An optical attenuator was attached to the multi-mode 
detector fiber to avoid saturating the highly sensitive APD. The forearm muscle went 
through three different physiological stages during the cuff occlusion on upper arm: 5-
minute resting baseline, 5-minute cuff inflation (230 mmHg), and 5-minute recovery 
following cuff deflation. 
Similar to the phantom data analysis the baseline µa and µs’ measured by the Imagent 
were used as inputs when fitting flow index αDB. Relative changes in αDB were 
calculated by normalizing/dividing the time-course data to the mean values of the 5-
minute resting baselines. The [Hb] and [HbO2] were calculated by adding their baseline 
values measured by the commercial Imagent and the corresponding ∆[Hb] and ∆[HbO2] 
measured by the DCS flow-oximeter. To be consistent with the phantom data analysis 
150 data points at each stage were used to calculate the corresponding SNRs. Standard 
errors were calculated over the 7 subjects and plotted as error bars along with the mean 
values in the figures. 
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6.2.5 SNR Calculations 
The variables measured by or derived from the DCS flow-oximeter include 𝑔2(𝒓, 𝜏), 
αDB/rBF, light intensity I, ∆µa, ∆[Hb] and ∆[HbO2]. SNR calculations for most of these 
variables follow the conventional definition (140):  
MEAN ( )
SNR
STD ( )
signal
noise
                                                          (6.3) 
Here, “STD” represents standard deviation, “MEAN” represents mean value, 
“signal” is the measured raw data, and “noise” is the high-frequency component of the 
measured raw data. The high-frequency noises originate from electronics, optics, 
positioning of the source and detectors, and physiological variations (only applicable to 
in vivo measurements) (9). The electronic noises include shot noise, thermal noise and the 
noise induced by the dark current of APD. The optic noises arise mainly from the fiber 
modal noise and the loss/variation of higher order modes due to the fiber 
bending/vibration. The physiological variations come from the respiration, heartbeat, and 
subject’s movement.  
The “noise” in Equation 6.3 for each set of measured raw data (150 data points) was 
obtained using a first order Butterworth high-pass filter with a corner frequency of 0.05 
Hz (83). This corner frequency was determined by analyzing the power spectral densities 
(PSDs) of the measured hemodynamic signals from forearm muscles, and was selected to 
be higher than the highest frequency (0.05 Hz) of the valid signals (i.e., slow 
hemodynamic changes during cuff occlusion) but lower than the DCS sampling rate 
(~0.4 Hz) and the highest frequency of noises. The MEAN (signal) may be equal to 0 for 
some variables (e.g., rBF ≈ 0 during cuff occlusion), resulting in zero SNR. In this case 
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the STD (noise) was used to evaluate measurement variability. 
Unlike those variables (described above) depending only on time (t), 𝑔2(𝒓, 𝜏)is a 
function of delay time τ at each measurement time point (t). To calculate the SNR of 
2 ( , )g r   at multiple τ, a previously established method is followed (83, 136):  
SN (𝜏) =
MEAN(𝑔2(𝒓,𝜏)−1)
STD(𝑔2(𝒓,𝜏)−1)
                                       (6.4) 
The calculation was carried out among the 150 datasets of (𝑔2(𝒓, 𝜏)-1). The MEAN 
and STD of the 150 (𝑔2(𝒓, 𝜏)-1) curves at each delay time τ were used to estimate SNR(τ) 
according to Equation 6.4. 
Differences among the three fibers in mean values of SNR or STD averaged over 7 
subjects were tested using the SAS (Statistical Analysis System) Version 9.3 software 
package and assessed by wavelength (only applicable to rBF) and during baseline, cuff 
occlusion, and recovery stages. Normality of the mean differences over 7 subjects was 
assessed using Shapiro-Wilks test (141). Any p-value less than 0.10 was considered to 
result in a departure from normality of the mean difference and a Wilcoxon Signed-Rank 
test (142) was used to assess whether the mean difference was significant in this case. 
Where there was no departure from normality the paired t-test was used to assess 
significance of the mean differences. A p-value of 0.05 was considered significant for the 
mean differences examined in SNR or STD of rBF between the single-mode and few-
mode fibers. A Bonferroni-corrected p-value of 0.017 (0.05/3) was considered significant 
for the mean differences examined in SNRs or STDs of [Hb] and [HbO2] between any 
two groups of single-mode, few-mode and multi-mode fibers. 
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6.3 Results 
6.3.1 Phantom Experimental Results 
Flow Measurement. During the phantom titration experiments µa (853 nm) was 
varied from 0.050 cm
-1
 to 0.150 cm
-1
 with a step size of 0.025 cm
-1 
while µs’ was kept 
constant (8 cm
-1
) throughout all steps. Figure 6.2a shows typical 𝑔2(𝒓, 𝜏) data (dots) and 
fitting curves (solid lines) recorded at 785 nm and collected by the single-mode (SM600) 
and few-mode (SM980) fibers. The data presented in Figure 6.2a were randomly 
selected from ~150 𝑔2(𝒓, 𝜏) curves over each titration step. As mentioned in Chapter 
6.2.1, β and DB can be simultaneously derived by fitting the measured 𝑔2(𝒓, 𝜏) . In 
addition, β can also be estimated based on the Siegert relation using the measured 
𝑔2(𝒓, 𝜏)  data at earliest τ and letting the normalized autocorrelation function 1g  ≈1, i.e., 
β = 2 ( 0)g    - 1. For example, the β values for the single-mode and few-mode fibers can 
be estimated by the intercept values of fitted 𝑔2(𝒓, 𝜏) curves, notated as A and B in 
Figure 6.2a. For the first titration (Step 1), the β values calculated over 150 
measurements were 0.46 ± 0.013 and 0.16 ± 0.013 for the single-mode (SM600) and few-
mode (SM980) fibers, respectively. Correspondingly, 1/β values were approximately 
equal to the numbers of guided modes of light (N): ~2 for the single-mode (SM600) fiber 
and ~6 for the few-mode (SM980) fiber. These numbers agreed with the theoretical 
values calculated based on fiber properties in Chapter 6.2.2. As µa increased the 2 ( , )g r   
curves became noisier for both single-mode and few-mode fibers. However, the curves 
collected by the few-mode fiber were always smoother than those recorded by the single-
mode fiber over the titration steps (Figure 6.2a). To further quantify the performance of 
92 
 
the two fibers we calculated the SNRs over 150 𝑔2(𝒓, 𝜏)  curves at each delay time τ for 
all titration steps using the method described in Chapter 6.2.5. Results shown in Figure 
6.2b indicated that the SNRs of 𝑔2(𝒓, 𝜏)  detected by the few-mode fiber were slightly 
higher than the single-mode fiber, which appeared more obvious at the early decay time τ. 
Similar results were found at the wavelength of 853 nm (data are not shown). 
 
Figure 6.2: (a) Typical 𝑔2(𝒓, 𝜏)  data (dots) and fitting curves (solid lines) recorded at 
785 nm and collected by the single-mode (SM600) and few-mode (SM980) fibers at five 
titration steps. The 𝑔2(𝒓, 𝜏)  curves are randomly selected at a single measurement time 
point t over 5 steps. The intercepts (e.g., A and B at Step 2) can be used to estimate β 
values (i.e., β = intercept value -1), which are the inverse of guided mode numbers (~2 
for SM600 and ~6 for SM980). (b) Corresponding SNRs calculated from the 150 
𝑔2(𝒓, 𝜏)  curves at each titration step. Figure 28 
 
 
The relative flow data (normalized DB) at five titration steps are shown in Figure 6.3a. 
Vertical lines separate different titration steps. Since multiple uncorrelated speckle 
fluctuations were collected by the multi-mode fiber (1mm) the measured autocorrelation 
function curve 𝑔2(𝒓, 𝜏)  became completely flat (a straight line) which cannot be fit using 
the algorithm described in Chapter 2.3. Therefore, only flow data (150 data points) 
collected by the single-mode and few-mode fibers were reported. As µa increased relative 
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flow data recorded at two wavelengths became noisier for both single-mode and few-
mode fibers, but the signal fluctuation observed when using the few-mode fiber was less 
than using the single-mode fiber. The difference in flow variations between the two fibers 
can be seen more clearly from Figure 6.3b where the STDs of noises are illustrated as 
error bars. Notice that flow increased slightly with the progress of titration which was 
likely due to the fitting errors at the titration steps with higher μa values associated with 
higher noises (83). Figure 6.3c shows the SNRs of relative flow at five titration steps 
calculated using Equation 6.3. The SNRs for both single-mode and few-mode fibers 
decreased as µa increased, and the few-mode fiber achieved slightly higher SNRs than the 
single-mode fiber. These results are consistent with the findings shown in Figures 6.3a 
and 6.3b. 
 
Figure 6.3: (a) Measured relative flow (normalized DB) during the phantom titration 
experiment detected by the single-mode (SM600) and few-mode (SM980) fibers at the 
two wavelengths (785 and 853 nm). (b) Mean values of relative flow and standard 
deviations of noise (error bars). (c) Corresponding SNRs of relative flow at the two 
wavelengths and five titration steps. Figure 29 
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Optical Property Measurements. Figure 6.4a displays the light intensities at two 
wavelengths collected by the three fibers during titrations. As expected, higher mode 
fibers collected more photons. Figure 6.4b shows the mean values of light intensities and 
STDs of noises (error bars) at five titration steps. In order to clearly show the error bars 
they were multiplied by a factor of 100. It can be observed from Figure 6.4b that with 
the increase of light intensity both MEAN (signal) and STD (noise) increased. The noise 
level increased because the higher light intensity increased shot noises from the photon 
detectors and random noises generated by photons transporting through the medium. 
Nevertheless, the increase of MEAN (signal) was larger than the increase of STD (noise). 
As a result, the SNR increased with the increase of light intensity (Figure 6.4c). The 
SNRs tended to decrease with the increase of μa, although such decreases were not 
remarkable at the early titration steps where the light intensities and SNRs were relatively 
high.  
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Figure 6.4: (a) Measured light intensities at the two wavelengths (785 and 853 nm) 
collected by the single-mode (SM600), few-mode (SM980) and multi-mode (1mm) fibers 
during the phantom titration experiment. The light intensity unit of “kcps” stands for kilo 
counts per second. (b) Averaged light intensities and standard deviations of noise (error 
bars) at the two wavelengths. The standard deviations of noise are multiplied by a factor 
of 100 to clearly display the error bars.  (c) Corresponding SNRs of light intensities at the 
two wavelengths and five titration steps. Figure 30 
 
 
The retrieved µa values at five titration steps and two wavelengths using the three 
fibers with different modes are displayed in Figure 6.5a. The µa (λ) value at the first 
titration step was assigned to be the theoretical value of the phantom (i.e., µa = 0.05 cm
-1 
at the wavelength of 853 nm). Figure 6.5b shows the mean values of μa and STDs of 
noises at five steps and two wavelengths. Again, in order to clearly show the error bars 
they were multiplied by a factor of 100. Horizontal dashed lines displayed in Figures 
6.5a and 6.5b indicate the theoretical μa values of the phantom at each step. All three 
fibers were able to extract µa with relatively small errors. The measurement error in μa 
was estimated by the percentage difference between the measured and theoretical values. 
The maximum measurement errors from the few-mode (1.6% at 785 nm and 1.3% at 853 
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nm) and multi-mode (4.3% at 785 nm and 4.8% at 853 nm) fibers were much smaller 
than those from the single-mode fiber (6.3% at 785 nm and 11% at 853 nm). Although 
differences in measurement error existed between the few-mode (≤ 1.6%) and multi-
mode (≤ 4.8%) fibers, the measurement errors (< 5%) from both fibers were comparable 
with previous NIRS results (< 6%) using multi-mode fibers (67, 71). The STDs of 
measurement noises (error bars) increased with the increase of µa and the decrease of 
fiber mode number. The SNRs of µa at the five steps and two wavelengths are displayed 
in Figure 6.5c. It is clear that higher SNRs for µa can be achieved by increasing the 
number of optical fiber modes. 
 
 
Figure 6.5: (a) Measured µa values at the two wavelengths (785 and 853 nm) collected 
by the single-mode (SM600), few-mode (SM980) and multi-mode (1mm) fibers during 
the phantom titration experiment. The horizontal dashed lines indicate theoretical µa 
values of the phantom at each step. (b) Averaged µa values and standard deviations of 
noise (error bars) at the two wavelengths. The standard deviations of noise are multiplied 
by a factor of 100 to clearly display the error bars.  (c) Corresponding SNRs of µa values 
at the two wavelengths and five titration steps. Figure 31 
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6.3.2 In vivo Tissue Measurement Results 
rBF Measurements. Figure 6.6a shows typical rBF data at 785 and 853 nm 
collected by the single-mode and few-mode fibers during 5-minute arterial cuff occlusion 
from one subject. Similar to phantom measurements the measured 𝑔2(𝒓, 𝜏)   curve 
collected by the multi-mode fiber (1mm) was a straight line which cannot be used to 
extract blood flow information. The raw rBF data (150 data points at each stage) were 
processed by the high-pass filter with a corner frequency of 0.05 Hz to extract the noises 
(Figure 6.6b). Vertical lines in Figures 6.6a and 6.6b separate different stages of 
occlusion (i.e., baseline, occlusion, recovery). The mean SNRs and standard errors (error 
bars) over 7 subjects at the baseline and recovery stages are displayed in Figure 6.6c. 
The SNRs of rBF at the occlusion stage were equal to zero and thus not reported. Instead, 
the STDs of rBF noises and their variations (standard errors shown as error bars) over 7 
subjects at all three stages are shown in Figure 6.6d. Assessed by SAS software (see 
Chapter 6.2.5), the p-values from the paired t-test/Wilcoxon Signed-Rank tests were 
larger than 0.222 indicating that the mean differences in SNR/STD of rBF over 7 subjects 
between the single-mode and few-mode fibers were not significant at all three stages of 
cuff occlusion. 
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Figure 6.6: (a) Typical forearm muscle rBF responses during 5-minute arterial cuff 
occlusion collected from one subject using the single-mode (SM600) and few-mode 
(SM980) fibers. (b) rBF noise processed by the high-pass filter with a corner frequency 
of 0.05 Hz. (c) Averaged SNRs of rBF and corresponding standard errors (error bars) of 
noise at baseline and recovery stages over 7 subjects. (d) Averaged standard deviations of 
high-frequency noises and corresponding standard errors (error bars) at baseline, cuff 
occlusion, and recovery stages over 7 subjects. Figure 32 
 
 
Oxygenation Measurements. Figure 6.7a displays the [Hb] and [HbO2] data during 
5-minute arterial occlusion measured by the three fibers with different modes from the 
same subject shown in Figure 6.6. Apparently, [Hb] and [HbO2] curves became 
smoother (Figure 6.7a) and noises were less (Figure 6.7b) when using higher mode 
fibers. Figure 6.7c displays the mean SNRs and their standard errors (error bars) over 7 
subjects. Assessed by SAS software (see Chapter 6.2.5), the p-values from the paired t-
test/Wilcoxon Signed-Rank tests were smaller than 0.016 when evaluating the 
significance between the few-mode and single-mode fibers and between the multi-mode 
and single-mode fibers. As noted in Chapter 6.2.5 a Bonferroni-corrected p-value of < 
0.017 was considered significant. This result indicated that the mean SNRs of both [Hb] 
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and [HbO2] using the few-mode and multi-mode fibers were significantly higher than 
those using the single-mode fiber.  
 
 
Figure 6.7: (a) Typical [Hb] and [HbO2] responses during 5-minute arterial cuff 
occlusion collected from the same subject shown in Figure 6.6 using the single- (SM600), 
few- (SM980) and multi-mode (1mm) fibers. (b) [Hb] and [HbO2] noises processed by 
the high-pass filter with a corner frequency of 0.05 Hz. (c) Averaged SNRs of [Hb] and 
[HbO2] and corresponding standard errors (error bars) of noises at baseline, cuff 
occlusion, and recovery stages over 7 subjects. Figure 33 
 
 
6.4 Discussion and Conclusions 
Traditional NIRS can measure tissue optical properties including μa, μs’, [Hb] and 
[HbO2] while the emerging DCS can measure rBF in deep tissues. By combining these 
two technologies to form a hybrid instrument, rBF, [Hb] and [HbO2] can be obtained 
simultaneously (55, 66). Consequently, relative changes in tissue oxygen metabolism can 
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be derived using simple models (55, 59, 66). While the hybrid instruments (NIRS + DCS) 
can be used to measure multiple hemodynamic/metabolic parameters providing deeper 
insights about tissue physiological status than one parameter alone, they are relatively 
large, complex and expensive. The dual-wavelength DCS flow-oximeter is an emerging 
technique enabling simultaneous measurements of tissue blood flow and oxygenation 
changes (41, 46, 67, 78, 127). Being noninvasive, fast, relatively inexpensive and truly 
portable (dimensions: 8”× 12”×18”), DCS flow-oximeter is suitable for bedside 
monitoring in the clinics. Furthermore, the new probe designed for the DCS flow-
oximeter shares source and detector fibers for both flow and oxygenation measurements. 
Therefore, it covers exactly the same tissue volume and avoids any discrepancies 
between the blood flow and oxygenation measurements owing to the tissue heterogeneity. 
For clinical measurements large light penetration is needed to probe optical properties 
in deep tissues (e.g., adult brain and muscle). According to photon diffusion theory a 
given source-detector (S-D) pair is mostly sensitive to the area at a depth of 1/3 to 1/2 of 
the S-D separation (45, 65, 67, 143). However, the larger the S-D separation the weaker 
the signal detected. Improving SNR is especially crucial when the detected signal is 
extremely low which is not unusual for DCS measurements in human tissues (40, 41, 54, 
75-78). 
According to Equation 6.3, SNR can be improved by increasing the light intensity 
injected into the tissue which is, however, not unlimited and has to be controlled to meet 
ANSI (American National Standards Institute) standards for laser safety usage. An 
alternative method is to use a low-pass filter to reduce the high frequency noises, but this 
may not be possible when the bandwidths of signal and noise are overlapped. This study 
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was designed to investigate the possibility of using the few-mode or multi-mode 
detection fibers instead of the single-mode fiber to increase the light intensity detected 
and thus improve SNRs of DCS flow-oximeter measurements. The rationale behind this 
hypothesis is that few-mode or multi-mode fibers allow higher order modes of light to be 
guided through along with the fundamental single mode which would increase the light 
intensity detected (135).  
To test the hypothesis the single-mode (SM600), few-mode (SM980) and multi-mode 
(1mm) fibers were examined in tissue-like liquid phantoms with varied optical properties 
and in forearm muscles during arterial cuff occlusion. The liquid phantom provided a 
homogeneous tissue model without the interference of physiological variations that exist 
in biological tissues (41, 67, 92), while the use of human muscles allowed for the 
evaluation of fiber performance in real tissues (39, 76, 77, 127, 128).  
The results obtained from the phantom titration experiments indicated that the few-
mode fiber slightly improved the SNRs of relative flow measurements compared to the 
single-mode fiber used (see Figure 6.3c). Although the slight SNR improvement in flow 
measurements was somewhat disappointing it was not surprising because the few-mode 
fiber with larger diameter and numerical aperture increased the detected signal intensity 
(see Figures 6.4a and 6.4b) but decreased the coherence factor β in a proportional 
fashion (see Figure 6.2a). A smaller β corresponded with a flatter autocorrelation 
function curve leading to a lower sensitivity of DCS flow measurements (60, 136). 
Therefore, the SNR of autocorrelation function, depending on both light intensity 
detected and coherence factor β (136), may not be highly improved (see Figure 6.2b). 
Although the detected light intensity can be further increased by using the multi-mode 
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fiber with a large diameter of 1 mm (see Figures 6.4a and 6.4b) the autocorrelation 
function was not detectable in this case due to the very low value of β. Furthermore, the 
SNR improvements were not obvious during in vivo rBF measurements in forearm 
muscles (see Figures 6.6c and 6.6d). Unlike phantom experiments in vivo measurements 
could be influenced by many factors such as physiological variations, motion artifacts, 
fiber-tissue coupling coefficient and tissue heterogeneity which could impact the 
measurements differently on different fibers (39, 54, 124, 128). Such in vivo “noises” 
may bury the slight SNR improvements of flow measurements observed in phantom 
experiments. 
In contrast to flow measurements, significant SNR improvements were achieved 
when using the few-mode or multi-mode fiber (versus single-mode fiber) in both 
phantom measurements of light intensity (see Figures 6.4c) and μa (see Figures 6.5c) 
and in in vivo measurements of [Hb] and [HbO2] (see Figures 6.7c). The significant SNR 
improvements for these variables were expected as they all depended on the light 
intensities detected which were highly different among the three fibers (see Figures 6.4a 
and 6.4b). The larger the number of optical fiber mode the higher the detected light 
intensity.  
The level of the detected light intensity also greatly impacted SNRs of the measured 
variables at different titration steps and different physiological stages. For example, with 
the increase of μa during the phantom titration the detected light intensity decreased step 
by step leading to a continual decrease in SNRs for all three fibers and two wavelengths 
(see Figures 6.3 and 6.4). One exception is the derived value of μa during phantom 
experiments where the SNRs of μa at the first titration step for both wavelengths were 
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lower than those at other steps (see Figures 6.5c), although the light intensities detected 
at the first step were higher (see Figures 6.4a and 6.4b). Since the μa values at the first 
titration step were much smaller than those at other steps (e.g., ~1.5 times smaller than 
the second step) but the STDs of μa at all steps didn’t vary much, it was not surprising 
that the SNRs of μa at the first titration step for both wavelengths were smaller than those 
at other steps according to Equation 6.3. Furthermore, the SNRs of [Hb] and [HbO2] 
during the cuff occlusion stage were lower than those at baseline and recovery stages for 
all three fibers (see Figure 6.7c) which was again due to the lower light intensities 
detected during occlusion compared to other two stages. In addition, the light intensity 
detected from the wavelength of 853 nm was ~2 times lower than the 785 nm wavelength 
(see Figures 6.4a and 6.4b) resulting in lower SNRs for the 853 nm wavelength at most 
titration steps and physiological stages (see Figures 6.3 to 6.6), although laser stability 
could also impact the SNRs.  
Besides the SNR improvements the few-mode and multi-mode fibers measured the 
optical property μa more accurately than the single-mode fiber (see Figures 6.5a and 
6.5b). Smaller measurement error represented higher measurement accuracy. The 
measurement errors in μa from the few-mode and multi-mode fibers were < 5% for both 
wavelengths (Figure 6.5a) which were comparable with those (< 6%) observed in 
previous studies using NIRS with multi-mode fibers (67, 71). The maximum errors from 
the single-mode fiber (< 11%) were much larger than those from the other two fibers 
(<5%) (Figure 6.5a) and those reported in literature (< 6%), which was again due to less 
light intensities collected (associated with higher noises) by the single-mode fiber.   
In conclusion, the experiments in this chapter demonstrated the advantages of using 
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the few-mode fiber for DCS flow-oximeter measurements of both blood flow and 
oxygenation compared to using the single-mode fiber. The few-mode fiber enabled 
collection of more photons from the phantoms/tissues resulting in higher SNRs in both 
flow and oxygenation measurements, although the SNR improvements with the few-
mode fiber were found to be significant only in oxygenation measurements. The multi-
mode fiber can further increase the detected light intensities and SNRs for tissue 
oxygenation measurements, but the autocorrelation functions for extracting flow 
information cannot be detected due to the very low value of β. 
Based on these results, selection of fibers with certain modes may depend on the 
particular application. For the measurements of blood flow only either single-mode fiber 
or few-mode fiber can be used, although the few-mode fiber may generate slightly higher 
SNRs of flow data. For simultaneous measurements of tissue blood flow and oxygenation 
using the dual-wavelength DCS flow-oximeter, a few-mode fiber (instead of single-mode 
fiber) should be used to obtain significantly higher SNRs of tissue oxygenation 
measurements. An alternative way is to use a detection fiber bundle consisting of one 
single-mode (or few-mode) fiber and one multi-mode fiber. The single-mode or few-
mode fiber can measure autocorrelation functions to extract flow information while the 
multi-mode fiber can detect light intensities at the two wavelengths with significantly 
higher SNRs (than both single-mode and few-mode fibers) to extract oxygenation 
information. However, the latter option requires two detectors connected to the fiber 
bundle which would increase the instrumentation costs.  
This pilot study was limited to comparing the SNRs of DCS flow-oximeter 
measurements among three types of fibers (i.e., single-mode, few-mode, multi-mode). 
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The selection of these specific three fibers was mainly based on fiber availability. The 
optimization of fiber modes used for achieving optimum SNRs in tissue hemodynamic 
measurements may be the subject of future study.  
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CHAPTER 7 STUDY SUMMARY, LIMITATIONS, AND FUTURE 
PERSPECTIVES 
 
7.1 Study Summary 
In this dissertation, I reported the development and application of ncDCT system for 
3-D blood flow imaging in human breast tumors. The imaging system utilized lens 
focusing apparatus to project source and detector fibers onto tissue surface. A motorized 
stage was integrated into the system for automated and customizable ROI scanning 
around tumor bearing region. A commercial 3-D camera was used to obtain breast 
surface geometry which was then converted to a solid volume mesh. Furthermore, a finite 
element framework was integrated to our DCT imaging algorithm which enabled blood 
flow imaging with arbitrary tissue geometry. System validation work including computer 
simulations and phantom experiments were performed to demonstrate the imaging ability 
of the ncDCT system for breast tumor detection. I also reported our first step to adapt the 
ncDCT system for tumor-to-normal blood flow contrast imaging from patients with 
breast tumors. In addition to this primary study, an optical fiber study was conducted to 
improve the SNR of DCS flow-oximeter measurement. The results reported in this 
dissertation have been presented in conferences and some of them have been published in 
peer-reviewed journals (see my attached CV).  
My major contributions in these studies include the following aspects: 
 First, I developed the imaging algorithms for ncDCT of breast tumor blood flow 
contrasts (Chapter 2) (37, 144). I designed computer simulations and conducted 
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phantom experiments to validate and optimize the algorithms and the ncDCT system 
(Chapters 3 and 4).  
Second, I participated in the design and construction of noncontact DCS/DCT system 
(Chapter 3) (37, 89, 92). I first involved in the design of a noncontact DCS (ncDCS) 
probe with single S-D separation. I designed and performed phantom and human tissue 
experiments to test the ncDCS probe. When extended the ncDCS to ncDCT, I further 
performed computer simulations to optimize the source and detector arrangement, and the 
scanning protocol for boundary data collection. To generate breast-shaped mesh, I 
utilized different commercial software (i.e., ScanStudio, Ansys and SolidWorks) to 
convert breast surface geometry, taken by a 3-D camera, to solid volume mesh for 
ncDCT image reconstruction.  
Third, for the first time I applied the ncDCT system on clinical breast tumor study 
(Chapter 5) (144). I recruited 28 patients with breast tumors and performed optical 
measurements. I was able to reconstruct 3-D images of tumor blood flow distributions 
inside breasts and the majority of reconstructed images showed higher blood flow 
contrasts in the tumor regions compared to the surrounding normal tissues. Reconstructed 
tumor depths and dimensions matched ultrasound imaging results when the tumors were 
within the sensitive region of light propagation. The results demonstrated that ncDCT 
system has the potential to image blood distributions in soft and vulnerable tissues 
without distorting tissue hemodynamics.  
Last, in order to improve the SNR of DCS flow-oximeter measurements, I 
experimentally explored using different detector fibers with different modes (i.e., single-
mode, few-mode, multimode) for photon collections (Chapter 6) (129). The outcomes 
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from this study provided useful guidance for the selection of optical fibers to improve 
DCS flow-oximeter measurements. 
 
7.2 Study Limitation and Future Perspectives 
 Tumor Location Recovery. The ncDCT imaging results from computer simulations 
and in vivo breast tumor measurements suggest that reconstructed tumor depths and 
dimensions are accurate when the anomaly/tumor was within the sensitive depth of 
diffuse light. When the tumor locates deeper than the maximal light penetration depth, 
lower part of the tumor cannot be sampled by the ncDCT probe (Figure 2.1a). 
Consequently, the reconstructed tumor location may be shifted up. Depth correction 
algorithms should be considered for the imaging process for improvement (106, 107); 
more weights may be added to elements located deep in the volume mesh when 
calculating the Jacobian matrix. On the other hand, prior knowledge of tumor location 
and dimension can also improve the recovery of tumor flow contrasts and locations using 
anatomical imaging modalities such as MRI or CT.  It should be noted that ncDCT 
cannot detect tumors located deeper than diffuse lights can reach. 
Tumor Flow Contrast Recovery. Even though the ncDCT system can detect the 
majority of breast tumors measured, we were unable to differentiate between malignant 
and benign tumors with the detected blood flow contrasts. This might be due to the 
overlap of blood flow contrast in different stages of malignant tumors and different types 
of benign lesions. Crosstalk between 𝜇𝑎, 𝜇𝑠
′  and BFI may also result in over- or under-
estimation of blood flow contrasts in ncDCT (67, 83). To overcome this limitation, a 
separate instrument enabling 3-D imaging of 𝜇𝑎 and 𝜇𝑠
′  distributions of breast tissue is 
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needed (e.g., a frequency-domain or time-resolved DOT (32, 120-122)). We can also 
increase the valid boundary measurement pairs by updating our line-shaped sources and 
detectors arrangement to 2-D array, so that the ill-posed inverse problem could be 
reduced to improve the flow contrast reconstruction accuracy.  
Clinical Limitations and Improvements. Current measurement protocol takes ~40 
minutes for each individual measurement. However, sometimes patients may move 
during the measurement, leading to motion artifacts or even the discontinuity of data 
collection. In the future, ncDCT measurement time should be reduced. The 2-D array of 
sources and detectors arrangement mentioned earlier can avoid the scanning procedure 
and thus avoiding such influence (145).    
It is expected that with further instrument and algorithm development and more 
clinical applications in large patient population, our ncDCT system may emerge as an 
alternative functional imaging modality to help detect/characterize different kinds of 
breast tumors. Furthermore, ncDCT can be used for other applications such wound tissue 
and pressure ulcer without distorting hemodynamic properties.   
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APPENDIX: GLOSSARY 
SYMBOLS 
α   Ratio of Dynamic to Static Scatterers (0-1) 
D   Photon Diffusion Constant 
DB   Effective Diffusion Coefficient 
g1   Normalized Electric Field Temporal Autocorrelation Function 
G1   Unnormalized Electric Field Temporal Autocorrelation Function 
g2   Normalized Intensity Temporal Autocorrelation Function 
I   Intensity 
k0   Wavevector of Photons in Medium (k0 = 2πn/λ) 
λ   Wavelength 
n   Ratio of Sample and Air Index of Refraction 
NA                                               Numerical Aperture 
φ   Phase Modulation of NIR Light 
ρ   Source-detector Separation 
r   Position Vector 
<Δr
2
(τ)>  Mean-square Displacement of Scatterers during τ 
S0   Source-light Distribution 
Φ                                 Photon Fluence Rate 
τ   Correlation Function Delay Time 
𝜏1                                 Selected Delay Time for DCT Image Reconstruction 
µs’   Reduced Scattering Coefficient 
µa   Static Absorption Coefficient 
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𝜇𝑎
𝑑                                Effective Dynamic Absorption 
𝜇𝑎
𝑡𝑜𝑡𝑎𝑙                          Total Absorption Coefficient 
ν   Speed of Light in Medium 
V                                 Fiber Normalized Frequency  
VC                               Fiber Cutoff Frequency 
[x]   Concentration of x 
ω   Angular Frequency of Modulation 
β                                  Coherence Factor 
λC                                                  Fiber Cutoff  Wavelength 
 
TERMS 
APD   Avalanche Photodiode 
BFI   Blood Flow Index (αDB) 
CW   Continuous Wave 
CT                               Computed Tomogaphy 
𝐶𝑣                                Coefficient of Variation 
DCS   Diffuse Correlation Spectroscopy 
(nc)DCT                     (noncontact) Diffuse Correlation Tomography 
DWS   Diffusing Wave Spectroscopy 
FD   Frequency Domain 
FWHM                        Full Width Half-maximum 
Hb   Deoxy-hemoglobin 
HbO2   Oxy-hemoglobin 
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J                                   Jacobian Matrix 
NIR   Near-Infrared 
NIRS   Near-Infrared Spectroscopy 
PET   Positron Emission Tomography 
RBC   Red Blood Cell 
rBF                             Relative Blood Flow 
S-D                             Source-Detector 
SNR   Signal to Noise Ratio 
StO2   Tissue Oxygen Saturation 
TD   Time Domain 
tHb   Total Hemoglobin 
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